WO2011142827A2

WO2011142827A2 - Diagnostic markers for neuropsychiatric disease

Info

Publication number: WO2011142827A2
Application number: PCT/US2011/000843
Authority: WO
Inventors: Steven E. Schutzer
Original assignee: Schutzer Steven E
Priority date: 2010-05-12
Filing date: 2011-05-12
Publication date: 2011-11-17
Also published as: US20130237454A1; DK2569446T3; EP2569446A4; AU2019204118B2; EP2569446A2; WO2011142827A3; AU2019204118A1; CA2799165A1; EP2569446B1; CA2799165C; AU2017202608A1; AU2011253481A1

Abstract

Biomarkers for the diagnosis of neuropsychiatric diseases are presented herein. In particular embodiments, biomarkers are identified that are useful for diagnosing multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease. Also encompassed is a method for diagnosing a patient with a neuropsychiatric disease, such as multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease, by analyzing biological samples isolated from the patient or the patient as a whole to assess levels of the biomarkers described herein.

Description

DIAGNOSTIC MARKERS FOR NEUROPSYCHIATRIC DISEASE

FIELD OF THE INVENTION

[0001] The present invention relates to identifying biologic markers (biomarkers) that can be used for diagnosis of a neuropsychiatric disease. As described herein, neuropsychiatric disease may be used to refer to diseases having neurologic or psychiatric or combined neurologic and psychiatric features. Such neuropsychiatric diseases include, without limitation, multiple sclerosis, chronic fatigue syndrome, and Neurologic Lyme disease. In particular embodiments, the present invention relates to identifying biomarkers for diagnosis of multiple sclerosis, chronic fatigue syndrome (CFS; also referred to herein as CF), or Neurologic Lyme disease. In a more particular aspect, the invention pertains to the identification of a biomarker signature that is diagnostic for each of multiple sclerosis, chronic fatigue syndrome, Neurologic Lyme disease. Accordingly, the invention further relates to a method for diagnosing a person or other mammal with a neuropsychiatric disease, such as multiple sclerosis, or at risk of developing same. The biomarkers and diagnostic signatures described herein also identify metabolic/biochemical pathways as potential candidates for therapeutic targeting. The invention further relates to guidance pertaining to appropriate treatment of the person or mammal diagnosed with a particular neuropsychiatric disease in accordance the methods described herein. Accurate diagnosis of neuropsychiatric disease, particularly with respect to diseases that are difficult to distinguish clinically, should reduce the duration and/or severity of the disease by ensuring that the patient is treated using an appropriate therapeutic regimen.

BACKGROUND OF THE INVENTION

[0002] Knowledge of the entire protein content, the proteome, of normal human

cerebrospinal fluid (CSF) would provide a critical standard to allow meaningful comparisons with and between neurologic and psychiatric disorders. CSF contains both cellular and soluble components providing insights into processes occurring in the central nervous system (CNS). As much as 30 to 40% of CSF is formed by the extracellular fluid of the brain and spinal cord. CSF contains both normal and disease specific components, and provides an accessible liquid window into the brain. In fact, recent data suggest CSF may provide more relevant evidence for initial or propagating pathology than the brain parenchyma itself in certain neuropsychiatric diseases [Ransohoff (2009) Nature 457: 155-156]. Comprehensive characterization of the normal CSF proteome, furthermore, facilitates identification of disease-specific markers [Ekegren et al. (2008) J Mass Spectrom 43: 559-571]. Knowledge of which proteins are present, absent, or of changed concentrations may lead to diagnostic, prognostic, or disease-activity biomarkers as well as provide insights into disease etiology and pathogenesis. An advantage of a full proteome analysis is the ability to identify not just one but a multitude of proteins at a single instance.

[0003] Multiple sclerosis, for example, is an excellent candidate disease for such an approach because it is often a progressive debilitating disease that is difficult to diagnose definitively, especially during the early stages of the disease. Multiple sclerosis is a common demyelinating disease of the central nervous system (CNS) that affects up to 0.1% of the Caucasian population of northern European descent. Multiple sclerosis is more common in women than men and generally begins between ages 20 and 40, but can develop at any age. Multiple sclerosis is generally viewed as an autoimmune syndrome directed against unidentified central nervous tissue antigens. The determination of susceptibility to multiple sclerosis development is complex and appears to be governed by both environmental and genetic factors. Some of the symptoms of multiple sclerosis are caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. When this nerve covering is damaged, nerve impulses are slowed down or stopped. Ultimately, damage to the myelin sheath results in nerve damage. Multiple sclerosis is, moreover, commonly a progressive disease that leads to more severe neurologic dysfunction over time. Nerve damage may be caused by inflammation that occurs when the body's immune cells attack the nervous system. Repeated episodes of inflammation can occur along any area of the brain and spinal cord, which is why the disease is often referred to as one characterized by symptoms and signs over time and space.

[0004] Multiple sclerosis is difficult to diagnose because the progress, severity and specific symptoms of multiple sclerosis are quite variable and unpredictable. There are no laboratory tests, symptoms or physical findings that can singly determine if a person has multiple sclerosis. The differential diagnosis of multiple sclerosis is quite varied and includes metabolic, genetic, oncologic, immunologic, and infectious disease assessment. Other diseases that may need to be considered in the differential diagnoses, but should be considered depending on the clinical presentation, include: Acute disseminated encephalomyelitis, CNS vasculitis, Behcet disease, Sjogren syndrome, Sarcoid, neoplasms, CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), Migrainous ischemia, Cerebrovascular disease, Progressive multifocal leukoencephalopathy, Inherited white matter diseases, effects of radiation therapy or drugs, CNS lymphoma, Lyme disease, HTLV-1 infection, CNS lupus, Mitochondrial encephalopathies,

Antiphospholipid antibody syndrome, cerebral emboli, Thrombocytopenic purpura, Progressive multifocal leukoencephalopathy, Mycoplasma encephalopathy, Vitamin B 12 deficiency,

Paraneoplastic syndromes, Psychiatric syndromes (Rolak LA, Fleming JO. The Neurologist 2007; 13: 57-72). Over the last twenty years, tests such as magnetic resonance imaging (MRI), examination of CSF, and evoked response testing have played an increasingly important role in the diagnostic process. In 2005, revised McDonald criteria for multiple sclerosis were published

(Polman et al. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald" Criteria. Ann Neurol. (2005) 58:840-846 and Polman et al. Ann Neurol (201 1) 69:292-302). In addition to the traditional diagnostic tools, the revised criteria provide specific guidelines for using findings of MRI, cerebrospinal fluid analysis and visual evoked potentials to support a diagnosis of multiple sclerosis. However, even with these revised criteria, diagnosis of multiple sclerosis is still challenging and frequently takes several months or even years.

[0005] Rendering a conclusive diagnosis of multiple sclerosis on an expedited basis would be of great benefit to patients in light of the potential for recurrence of attacks and progression of the disease. Drugs for the treatment of multiple sclerosis are now available which slow or prevent progression of the disease in many patients, and an early diagnosis would, therefore, allow early intervention and could significantly improve the quality of life for many multiple sclerosis patients.

[0006] It is therefore an object of the present invention to provide an efficient diagnosis system for neuropsychiatric disease in general, a particular example of which is multiple sclerosis, so as to provide biomarkers with which a clinician can diagnose or exclude a particular disease in a patient or other mammal. The same reasoning applies to Neurologic Lyme Disease and Chronic Fatigue syndrome.

[0007] The citation of references herein shall not be construed as an admission that such is prior art to the present invention. Several publications and patent documents are referenced in this application in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these publications and documents is incorporated by reference herein. [0008] Other features and advarttages o'f the invention will be apparent from the detailed description, the drawings, and the claims.

SUMMARY OF THE INVENTION

[0009] The present invention is based on the discovery of biomarkers useful for diagnosing and monitoring neuropsychiatric diseases. Neuropsychiatric diseases which may be diagnosed or monitored using the biomarkers of the invention include, without limitation: multiple sclerosis (especially focused on first attack multiple sclerosis), Neurologic Lyme Disease, and Chronic Fatigue Syndrome. Biomarkers identified for such neuropsychiatric diseases are listed herein in Tables lm, 2m, 3, 4H-m, 4H-1, 4H-c, 5c, 6c, 7L, 8L, 9, and 10. As indicated in the tables presented herein, the presence or absence of at least one biomarker in a biological sample isolated from a patient is indicative of a positive diagnosis of a neuropsychiatric disease. As indicated herein, the identification of a plurality of biomarkers correlated with a particular disease may strengthen the confidence level of the diagnostic prediction. Biomarkers identified herein have also been assessed using software programs (such as, e.g., Ingenuity Pathway Analysis) to identify metabolic pathways implicated in disease etiology, maintenance, and/or progression. Multiple hits in a particular metabolic pathway underscore the potential importance of the pathway for the disease and direct therapeutic intervention toward appropriate modulation of same.

[00010] Accordingly, the present invention is directed to a method for diagnosing a neuropsychiatric disease in a patient, wherein said method comprises isolating a biological sample from the patient and analyzing the biological sample to determine if at least one of the biomarkers indicative of the presence of the neuropsychiatric disease is identified in the biological sample, thereby diagnosing the neuropsychiatric disease in the patient. As described herein, the presence or absence of at least one biomarker in a biological sample isolated from a patient is indicative of a positive diagnosis of a neuropsychiatric disease.

[00011] In another aspect, a method for diagnosing multiple sclerosis in a patient is presented, the method comprising: a) isolating a biological sample from the patient; and b) analyzing the biological sample for expression of a panel of biomarkers, wherein the panel of biomarkers is set forth in any one of Tables lm, 3m, 4H-m or 2m, to determine if at least one of the biomarkers listed in any one of Tables lm, 3m, 4H-m or Table 2m is identified in the biological sample, wherein identification of at least one of the bionlarkers in the biological sample indicates a positive diagnosis or is indicative of multiple sclerosis in the patient. In an embodiment thereof, the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table lm, 3m, or 4H-m, and the presence of the at least one biomarker indicates a positive diagnosis or is indicative of multiple sclerosis. In another embodiment, the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 2m and the absence of the at least one biomarker indicates a positive diagnosis or is indicative of multiple sclerosis.

[00012] In yet another aspect, a method for differentially diagnosing a neuropsychiatric disease in a patient is presented, wherein the patient exhibits clinical symptoms common to both Neurologic Lyme disease and Chronic Fatigue Syndrome, the method comprising: a) isolating a biological sample from the patient; and b) analyzing the biological sample for expression of a first panel of biomarkers, wherein the first panel of biomarkers is set forth in any one of Tables 4H-1, 7L, or 8L, to determine if at least one of the biomarkers listed in any one of Tables 4H-1, 7L, or 8L is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis or is indicative of Neurologic Lyme disease. In an embodiment thereof, the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-1 or 7L and the presence of the at least one biomarker indicates a positive diagnosis or is indicative of Neurologic Lyme disease. In another embodiment, the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 8L and the absence of the at least one biomarker indicates a positive diagnosis or is indicative of Neurologic Lyme disease.

[00013] The method may further comprise analyzing the biological sample for expression of a second panel of biomarkers, wherein the second panel of biomarkers is set forth in any one of Tables 4H-c, 5c, or 6c, to determine if at least one of the biomarkers listed in any one of Tables 4H-c, 5c, or 6c is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome. In an embodiment thereof, the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-c or 5c and the presence of the at least one biomarker indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome. In another embodiment, the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 6c and the absence of the at least one biomarker indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome.

[00014] In yet another aspect, a method for diagnosing Neurologic Lyme disease in a patient is presented, the method comprising: a) isolating a biological sample from the patient; and b) analyzing the biological sample for expression of a panel of biomarkers, wherein the panel of biomarkers is set forth in any one of Tables 4H-1, 7L, or 8L, to determine if at least one of the biomarkers listed in any one of Tables 4H-1, 7L, or 8L is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis or is indicative of Neurologic Lyme disease in the patient. In an embodiment thereof, the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-1 or 7L, and the presence of the at least one biomarker indicates a positive diagnosis or is indicative of Neurologic Lyme disease. In another embodiment, the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 8L and the absence of the at least one biomarker indicates a positive diagnosis or is indicative of Neurologic Lyme disease.

[00015] In yet another aspect, a method for diagnosing Chronic Fatigue Syndrome in a patient is presented, the method comprising: a) isolating a biological sample from the patient; and b) analyzing the biological sample for expression of a panel of biomarkers, wherein the panel of biomarkers is set forth in any one of Tables 4H-c, 5c, or 6c , to determine if at least one of the biomarkers listed in any one of Tables 4H-c, 5c, or 6c is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome in the patient. In an embodiment thereof, the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-c or 5c, and the presence of the at least one biomarker indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome. In another embodiment, the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 6c and the absence of the at least one biomarker indicates a positive diagnosis or is indicative of Chronic Fatigue Syndrome. [00016] In accordance with the methods described herein, the biological sample may be cerebrospinal fluid, blood or a component thereof (e.g., plasma, serum, cells), tissue or tissue-related fluids, urine, or saliva.

[00017] Also encompassed herein is a method for diagnosing a neuropsychiatric disease, the method comprising: a) isolating a biological sample from the patient; b) analyzing the biological sample to determine a first level of at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the biological sample; and c) comparing the first level of the at least one of the biomarkers to a second level of the at least one of the biomarkers determined for a subject, wherein the subject does not have the neuropsychiatric disease, and wherein at least a two-fold difference in the ratio of the first level to the second level indicates a positive diagnosis of the neuropsychiatric disease. In a particular embodiment, the at least two-fold difference is an increase, which is indicative of a positive diagnosis of the neuropsychiatric disease. In an alternative embodiment, the at least two-fold difference is a decrease, which is indicative of a positive diagnosis of the neuropsychiatric disease. As described herein, in certain circumstances the subject is a healthy subject. In accordance with the invention, the subject may have a second neuropsychiatric disease, wherein the second neuropsychiatric disease differs from the neuropsychiatric disease for which the instant method is diagnostic. Under such a circumstance, the two-fold difference in the ratio may be used to confer a differential diagnosis between the neuropsychiatric disease for which the instant method is diagnostic and the second neuropsychiatric disease. This is a particularly useful feature of the present method when the clinical presentation for the neuropsychiatric disease for which the instant method is diagnostic and the second neuropsychiatric disease is similar.

[00018] In a particular embodiment thereof, a method is presented for diagnosing a neuropsychiatric disease in a patient, wherein the patient exhibits clinical symptoms common to both Chronic Fatigue Syndrome and Neurologic Lyme disease, the method comprising: a) isolating a biological sample from the patient; b) analyzing the biological sample to evaluate expression levels of the biomarkers listed in Table 9 to determine a first level of at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the biological sample; and c) comparing the first level of the at least one of the biomarkers to a second level of the at least one of the biomarkers determined for a subject, wherein the subject does not have the neuropsychiatric disease, and wherein at least a two-fold difference in the ratio of the first level to the second level indicates a positive diagnosis of the neuropsychiatric disease. In an embodiment thereof, the diagnosis is directed to determining if the patient has Chronic Fatigue Syndrome or Neurologic Lyme disease. In a particular embodiment, the at least a two-fold difference is at least a two-fold increase or at least a two-fold decrease. In another particular embodiment, the subject is a healthy subject.

[00019] Also encompassed herein are kits for diagnosing neuropsychiatric diseases. In a particular aspect, a kit for diagnosing multiple sclerosis is presented, wherein the kit comprises probes (e.g., antibodies or fragments or derivatives thereof) for detecting expression of at least one biomarker listed in Table lm, 3m, 4H-m, or Table 2m, wherein detectable expression of at least one biomarker listed in Table lm, 3m, or 4H-m is indicative of a positive diagnosis of multiple sclerosis and wherein an absence of detectable expression of at least one biomarker listed in Table 2m is indicative of a positive diagnosis of multiple sclerosis.

[00020] In another aspect, a kit for diagnosing Chronic Fatigue Syndrome is presented, wherein the kit comprises probes (e.g., antibodies or fragments or derivatives thereof) for detecting expression of at least one biomarker listed in Table 4H-c, 5c, or Table 6c, wherein detectable expression of at least one biomarker listed in Table 4H-c or 5c is indicative of a positive diagnosis of Chronic Fatigue Syndrome and wherein an absence of detectable expression of at least one biomarker listed in Table 6c is indicative of a positive diagnosis of Chronic Fatigue Syndrome.

[00021] In yet another aspect, a kit for diagnosing Neurologic Lyme Disease is presented, wherein the kit comprises probes (e.g., antibodies or fragments or derivatives thereof) for detecting expression of at least one biomarker listed in Table 7L or Table 8L, wherein detectable expression of at least one biomarker listed in Table 7L is indicative of a positive diagnosis of Neurologic Lyme Disease and wherein an absence of detectable expression of at least one biomarker listed in Table 8L is indicative of a positive diagnosis of Neurologic Lyme Disease.

[00022] As described herein, the kits embodied herein may comprise probes for detecting expression of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 of the biomarkers listed in any one of Tables lm, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L, wherein the number of biomarkers listed in any one of Tables lm, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L establishes the upper limit of biomarkers detected by the kit. In other words, each of the Tables encompasses a maximum number of biomarkers as indicated therein and the number of biomarkers listed in the Tables may differ between each Table. In a particular embodiment, a kit may comprise probes for detecting expression of all of the biomarkers listed in any one of Tables lm, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L. In particular embodiments, the probes may be immobilized on a solid surface.

[00023] In another aspect, the invention is directed to a method for monitoring efficacy of a treatment for a neuropsychiatric disease in a patient, wherein said method comprises isolating a first biological sample from the patient prior to initiating the treatment and isolating a second biological sample from the patient after initiating the treatment, analyzing the biological samples to determine the level of at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the first and second biological samples, and comparing the level of the at least one of the biomarkers in the first and second biological samples, wherein a change in the level of the at least one of the biomarkers reflects the efficacy of the treatment. In one embodiment, wherein the presence of the at least one biomarker is associated with a positive diagnosis or presence of the disease, a detectable reduction in the level of the at least one biomarker following initiating the treatment indicates that the treatment is efficacious. In another embodiment, wherein the absence of the at least one biomarker is associated with a positive diagnosis or presence of the disease, a detectable increase in level in the at least one biomarker following initiating the treatment indicates that the treatment is efficacious.

[00024] In another aspect, the invention is directed to a method for monitoring disease progression of a neuropsychiatric disease in a patient, wherein said method comprises isolating a first biological sample from the patient at an initial or first temporal window and isolating a second biological sample from the patient at a later (e.g., second) temporal window, analyzing the biological samples to determine the level of at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the first and second biological samples, and comparing the level of the at least one of the biomarkers in the first and second biological samples, wherein a change in the level of the at least one of the biomarkers in the first and second biological samples reflects progression of the disease. In one embodiment, wherein the presence of the at least one biomarker is associated with a positive diagnosis or presence of the disease, a detectable increase in the level of the at least one biomarker at the later temporal time window relative to the initial temporal window indicates that the disease has progressed or worsened. In another embodiment, wherein the absence of the at least one biomarker is associated with a positive diagnosis or presence of the disease, a detectable decrease in the level of the at least one biomarker at the later temporal time window relative to the initial temporal window indicates that the disease has improved.

[00025] The present invention is, moreover, directed to a method for diagnosing a

neuropsychiatric disease in a patient, wherein said method comprises visualizing or detecting at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the patient, thereby diagnosing the neuropsychiatric disease in the patient. As described herein, the presence or absence of at least one biomarker in a patient is indicative of a positive diagnosis of a

neuropsychiatric disease. In accordance with such an embodiment, various detection imaging techniques may be utilized including, but not limited to, magnetic resonance imaging (MRI), positron emission tomography (PET), and CAT scans.

[00026] In one embodiment, the present invention relates to the identification and use of biomarkers in methods for diagnosing multiple sclerosis, particularly diagnosis of first attack multiple sclerosis. The invention also pertains to the use of these biomarkers in methods for assessing relapse of multiple sclerosis patients and disease progression in multiple sclerosis patients. Biomarkers identified in accordance with the invention are also useful for identifying treatments for and monitoring efficacy of treatment of patients with multiple sclerosis. As shown herein, the inventors have identified a plurality of biomarkers whose presence is indicative of multiple sclerosis; such biomarkers are listed in Tables lm, 3m, or 4H-m. The inventors have also identified a plurality of biomarkers whose absence is indicative of multiple sclerosis; such biomarkers are listed in Table 2m.

In another embodiment, the present invention relates to the identification and use of biomarkers in methods for diagnosing chronic fatigue syndrome (CFS) in patients. Biomarkers identified in accordance with the invention are also useful for identifying treatments for and monitoring efficacy of treatment of patients with CFS. As shown herein, the inventors have identified a plurality of biomarkers whose presence is indicative of CFS; such biomarkers are listed in Table 4H-c, and 5c. The inventors have also identified a plurality of biomarkers whose absence is indicative of CFS; such biomarkers are listed in Table 6c.

[00027] In yet another embodiment, the present invention relates to the identification and use of biomarkers in methods for diagnosing Neurologic Lyme disease in patients. Biomarkers identified in accordance with the invention are also useful for identifying treatments for and monitoring efficacy of treatment of patients with Neurologic Lyme disease. As shown herein, the inventors have identified a plurality of biomarkers whose presence is indicative of Neurologic Lyme disease; such biomarkers are listed in Table 7L. The inventors have also identified a plurality of biomarkers whose absence is indicative of Neurologic Lyme disease; such biomarkers are listed in Table 8L.

[00028] Also encompassed herein are diagnostic signatures for neuropsychiatric diseases.

Such diagnostic signatures comprise biomarkers for diagnosing a neuropsychiatric disease, wherein the presence or absence of at least one biomarker indicates a positive diagnosis of the

neuropsychiatric disease. In particular aspects, the diagnostic signature is indicative of multiple sclerosis, Chronic Fatigue Syndrome, or Neurologic Lyme Disease. In a particular embodiment, the diagnostic signature relates to the presence of at least one biomarker listed in Table lm, 3m, or 4H- m and is indicative of a positive diagnosis of multiple sclerosis. In another embodiment, the diagnostic signature relates to the absence of at least one biomarker listed in Table 2m and is indicative of a positive diagnosis of multiple sclerosis. In yet another embodiment, the diagnostic signature relates to the presence of at least one biomarker listed in Table 4H-c or 5c and is indicative of a positive diagnosis of Chronic Fatigue Syndrome. In a further embodiment, the diagnostic signature relates to the absence of at least one biomarker listed in Table 6c and is indicative of a positive diagnosis of Chronic Fatigue Syndrome. In another embodiment, the diagnostic signature relates to the presence of at least one biomarker listed in Table 7L and is indicative of a positive diagnosis of Neurologic Lyme Disease. In yet another embodiment, the diagnostic signature relates to the absence of at least one biomarker listed in Table 8L and is indicative of a positive diagnosis of Neurologic Lyme Disease.

BRIEF DESCRIPTION OF THE DRAWINGS

[00029] Figure 1 shows a Venn diagram revealing the amount of overlap of the present dataset with a comparable dataset of proteins detected in the CSF of "normal clinical value" or "neurologic surrogate-normal" individuals who required a lumbar puncture for clinical reasons as reported by Zougman et al. [(2008) J Proteome Res 7: 386-399]. The large circle represents the 2630 proteins observed in the present comprehensive dataset of proteins detected in the CSF of normal individuals. The small c xle represents the 798 proteins identified in the analysis by

Zougman et al. [(2008) J Proteome Res 7: 386-399].

DETAILED DESCRIPTION OF THE INVENTION

[00030] The present inventors had a unique opportunity to generate what may be the most comprehensive database of true normal CSF proteins to date. The inventors were able to do this because they had sufficient numbers and total volume of true normal CSF samples to employ immunoaffinity depletion, followed by extensive fractionation and high-resolution liquid

chromatography (LC) separation and mass spectrometry (MS) analysis. The combination of the normal CSF samples, including a set of serial CSF samples, and advanced technology contribute to the uniqueness and value of the present study. Knowledge as to the normal CSF proteome, in turn, makes possible a meaningful comparison with disease proteomes (i.e., proteomes characteristic of a particular disease).

[00031] Until recently, technological limitations have prevented full characterization of the

CSF proteome. Comprehensive analysis of CSF has been challenged by low protein levels (0.3 to 0.7 mg/ml) compared to plasma, protein concentration variability up to twelve orders of magnitude, potential masking of brain-specific proteins by highly abundant proteins [Rozek et al. (2007) J Proteome Res 6: 4189-4199], and limited access to an adequate number of appropriate biological samples. Despite some of these limitations, a number of earlier studies have provided increasing levels of characterization of the CSF proteome. For the most part, these studies have used pooled samples from patient populations with diseases or from people with normal CSF clinical laboratory values (chemistries, cell counts, and microbiology) who underwent lumbar puncture for

investigation of neurological complaints. These CSF samples were used as substitutes or surrogates for true normals (healthy volunteers) possibly due to lack of availability of such normal CSF samples. Sickmann et al., [(2000) Electrophoresis 21 : 2721-2728] used two-dimensional

polyacrylamide gel electrophoresis (2D-PAGE) followed by mass spectrometry (MS) to identify close to 70 CSF proteins. Yuan et al., [(2005) Proteomics 5: 541-550] used matrix-assisted laser desorption ionization (MALDI) MS to identify 22 proteins in desalted CSF. Wenner et al., [(2004) J Proteome Res 3: 97-103] used 2D liquid chromatography (LC) coupled to tandem mass

spectrometry (2D-LC-MS/MS) to identify 249 proteins in pooled CSF. Maccarrone et al. [(2004) Electrophoresis 25: 2402-2412]^ used immunodepletion techniques and shotgun LC-MS/MS, to identify more than 100 proteins in CSF from a patient with normal pressure hydrocephalus. More recently Zougman et al. [(2008) J Proteome Res 7: 386-399], using LC-MS/MS, reported 798 proteins in a pool of 6 patients with neurologic complaints that warranted a lumbar puncture, but whose subsequent clinical CSF laboratory values were reported as normal; for the purposes of this application these types of patients as referred to as neurologic surrogate-normals. A notable exception to use of surrogates was the work by Zhang et al. [(2005) Neurobiol Aging 26: 207-227], who used 2D-LC-MS/MS to identify 315 proteins in pools of CSF comparing healthy younger versus older individuals. Subsequently, with Xu et al. [(2006) Int Rev Neurobiol 73: 29-98], they analyzed CSF from the younger group with two different LC-MS/MS platforms and identified a combined total of 915 proteins. Pan et al., reported a total of 2594 CSF protein identifications from different combined (cumulative) results of several CSF studies with a focus on neurodegenerative diseases such as Alzheimer's disease [(2007) Proteomics 7: 469-473].

[00032] Towards the principal purpose of establishing a comprehensive list or proteome of normal CSF, the present inventors have prepared CSF samples from healthy normal people for analysis by using immunoaffinity depletion of abundant proteins (with masking potential) to enhance coverage and detection of low abundance proteins [Qian et al. (2009) J Proteome Res 8: 290-299]. It is noteworthy that the present inventors also analyzed the abundant sample fraction in parallel.

Samples were then analyzed employing high throughput, high sensitivity, and high resolution nanocapillary liquid chromatography-mass spectrometry (LC-MS [Petyuk et al. (2007) Genome Res 17: 328-336] and LC-MS/MS [Qian et al. (2009) J Proteome Res 8: 290-299]). Pre-fractionation (immunoaffinity depletion chromatography) and ultra-high resolution nanocapillary LC separations were used to effectively reduce the sample complexity and concentration dynamic range (thereby reducing or eliminating the "masking" effect [Ramstrom et al. (2005) J Proteome Res 4: 410-416]), high efficiency ion transmission technologies (e.g., electrodynamic ion funnel [Shaffer et al. (1997) Rapid Commun Mass Spectrom 1 1 : 1813-1817]) for highly sensitive global MS analysis, and the accurate mass and time (AMT) tag strategy [Smith et al. (2002) Proteomics 2: 513-523] for high- throughput analysis (e.g. of individual CSF samples) and accurate quantitation. The general approach for AMT tag generation and application as described herein has been successfully implemented for whole microbial [Lipton et al. (2002) Proc Natl Acad Sci U S A 99: 1 1049-1 1054] and mammalian tissue [Petyuk et al. (2007) Genome Res 17: 328-336] and plasma proteomes [Qian et al. (2009) J Proteome Res 8: 290-299; Qian et al. (2005) Mol Cell Proteomics 4: 700-709], but has not been previously applied to CSF from normal subjects.

[00033] As described herein, pooled CSF isolated from 1 1 normal healthy volunteers (8 women and 3 men, aged 24 to 55, median = 28 years) who reported their health as excellent or good and were taking no medications was examined. Standard clinical laboratory testing on their CSF was normal (none had more than 3 white blood cells/mm³ and protein levels ranged from 14 to 40 mg/dl with a median of 25 mg/dl). Also examined were pairs of individual serial CSF samples, obtained at least 4 weeks apart, from 10 additional normal healthy volunteers to assess the potential variability of particular CSF protein levels in an individual from one time point to another.

[00034] To illustrate the utility of such a normal database and how one clinical condition might be compared to another the present inventors also analyzed and compared one set of CSF samples to another set processed in the same manner to evaluate, among other issues, if there might be significant differences among different surrogate-normal groups.

[00035] In summary and as described in greater detail herein below, the present inventors applied immunoaffinity separation and high sensitivity and resolution liquid chromatography-mass spectrometry to examine CSF from healthy normal individuals. 2630 proteins in CSF from normal subjects were identified, of which 56% were CSF-specific (i.e., as determined using the techniques described herein), not found in the much larger set of 3654 proteins identified in plasma. The above- mentioned 2630 proteins identified in normal subjects were identified with high confidence, meaning that two or more peptides corresponding to a particular protein were required as

confirmation that the particular protein was, indeed, present in normal CSF. The present inventors also examined CSF from groups like those of subjects previously examined by others as surrogates for normals, where neurologic symptoms warranted a lumbar puncture but where clinical laboratory were reported as normal. Statistically significant differences between their CSF proteins and those determined for non-neurological normals examined herein were noted. The inventors also examined CSF from 10 volunteer subjects who had lumbar punctures at least 4 weeks apart and found that there was little variability in CSF proteins in an individual as compared from subject to subject.

[00036] The present results represent the most comprehensive characterization of true normal CSF to date. This normal CSF proteome establishes a comparative standard and basis for investigations into a variety of dlseases^'with neurological and psychiatric features. With this essential information, the present inventors were able to identify biomarkers diagnostic for a number of neuropsychiatric diseases. See Examples I-IV.

[00037] Accordingly, the present invention encompasses identification of biomarkers diagnostic for a number of neuropsychiatric diseases. As indicated in each of Tables 1-10, the present inventors have identified biomarkers, whose presence or absence as indicated herein is a positive indicator of the presence of a neuropsychiatric disease in a patient. Thus, the presence or absence of at least one biomarker for a neuropsychiatric disease serves as a diagnostic tool for clinicians. It is understood that a clinician will evaluate a patient as a whole based on known criteria well established in the field for diagnosis of a neuropsychiatric disease and utilize the diagnostic method of the present invention in conjunction with such known diagnostic criteria to establish a definitive diagnosis.

[00038] According to the present invention, the term "neuropsychiatric diseases" refers to, without limitation, multiple sclerosis and in particular first attack or early multiple sclerosis, Neurologic Lyme Disease, Chronic Fatigue Syndrome, and other diseases with similar features that may place them in the differential diagnosis in evaluating a patient.

[00039] According to the present invention, the term "multiple sclerosis" is used to describe the art-recognized disease characterized by inflammation, demyelination, oligodendrocyte death, membrane damage, other neurologic damage, and axonal death. Multiple sclerosis can be characterized as one of four main varieties as defined in an international survey of neurologists (Lublin and Reingold, 1996, Neurology 46(4):907-l 1), which are namely: Relapsing-Remitting multiple sclerosis (RRMS), Primary Progressive multiple sclerosis (PPMS), Secondary-Progressive multiple sclerosis (SPMS), Progressive-Relapsing multiple sclerosis (PRMS).

[00040] According to the present invention, the term "Neurologic Lyme Disease" is used to describe a range of neurologic or psychiatric manifestations that may be associated with Lyme disease. As referred to herein, "Neurologic Lyme Disease" encompasses the range from an acute neurologic syndrome in an acute case of active Lyme Disease and late manifestation of Lyme disease (both sometimes referred to as neuroborreliosis), to the more poorly defined post-treatment Lyme disease syndrome and "chronic Lyme Disease" [00041] According to the present invention, the term "Chronic Fatigue Syndrome" is used to describe a constellation of symptoms including fatigue that approach those described in the 1994 proposed case definition [Fukuda et al, Annals of Internal Medicine, Vol. 121, December 15, 1994, pp. 953-959] that are subject to revision. In practice it is often a clinical diagnosis of exclusion.

[00042] As used herein, the terms "patient" or "subject" are used interchangeably. Such patients may have a neuropsychiatric disease or disorder, such as multiple sclerosis, CFS, and Neurologic Lyme Disease. With respect to multiple sclerosis, for example, the terms " multiple sclerosis patient", "a subject who has multiple sclerosis ", "a patient who has multiple sclerosis ", "a multiple sclerosis subject", and similar phrases, are intended to refer to subjects who have been diagnosed with multiple sclerosis.

[00043] The terms "healthy subject" or "normal subject", and similar phrases, are intended to refer to a subject who has not been diagnosed with a neuropsychiatric disease or disorder. A healthy subject has no other acute systemic disease or, at the least, has no detectable acute systemic disease. With respect to aspects of the invention directed to, for example, multiple sclerosis, the terms "healthy subject", "non- multiple sclerosis subject", "a subject who does not have multiple sclerosis ", "a patient who does not have multiple sclerosis ", and similar phrases, are intended to refer to a subject who has not been diagnosed with multiple sclerosis.

[00044] As used herein, the term "patient" or "subject" may refer to a mammal, including a human.

[00045] As used herein, the term "biological sample" includes a sample of any cell type or from any tissue or body fluid, body fluids including, but not limited to: cerebrospinal fluid (CSF), blood (whole blood, serum, plasma, or cellular components) , saliva, urine, prostatic fluid, or fluid from any suitable tissue. In a particular embodiment, the biological sample is CSF. In another embodiment, the biological sample is blood or any component of blood (e.g., serum, plasma, cells, etc.).

[00046] The term "protein" is used herein to mean protein, polypeptide, oligopeptide or peptide. The terms "biologic marker", "biomarker" or "disease-associated protein" are used herein to refer to proteins associated with specific diseases or conditions, including proteins from organs or tissues ("organ-specific" or "tissue-specific" proteins) affected by a disease or condition. In accordance with the present invention, the presence or absence of a biomarker is positively correlated with, indicative of, or diagnostic for the presence of a disease or condition, such as a neuropsychiatric disease, in a patient. Also in accordance with the present invention, a relative increase in levels of a particular biomarker or biomarkers as compared to a control or normal subject can also be positively correlated with, indicative of, or diagnostic for the presence of a disease or condition, such as a neuropsychiatric disease, in a patient.

[00047] The present invention, furthermore, encompasses a plurality of biomarkers or a

"biomarker signature" that is positively correlated with, indicative of, or diagnostic for the presence of a disease or condition, such as a neuropsychiatric disease, in a patient. Accordingly, the presence or absence of a biomarker signature is positively correlated with, indicative of, or diagnostic for the presence of a disease or condition, such as a neuropsychiatric disease, in a patient. A biomarker signature may also encompass a plurality of biomarkers that exhibit a relative increase or decrease in levels as compared to a healthy or normal subject (e.g., a control subject) and is positively correlated with, indicative of, or diagnostic for the presence of a disease or condition, such as a

neuropsychiatric disease, in a patient.

[00048] A skilled practitioner would, moreover, appreciate that the presence or absence of a particular protein in a sample may be weakly indicative of disease, but not diagnostic, if noted as a single determinant. If, however, a plurality of such single determinants are noted in a biological sample, the combined detection of several weakly indicative determinants may serve to identify a strong combinatorial diagnostic indicator of disease. Furthermore, the single protein/determinant need not even approach the threshold of weak diagnostic by itself but in combination with the detection or absence of detection of another protein or proteins may serve as a strong combinatorial diagnostic indication of a disease state. Accordingly, also encompassed herein are combinatorial diagnostic indicators that are associated with a particular disease and not observed in healthy subjects or patients with other diseases.

[00049] Accordingly, selected sets of one, two, three, and more of the biomarkers of this invention (up to the number equivalent to all of the biomarkers, including any intervening number, in whole number increments, e.g., 1, 2, 3, 4, 5, 6 . . . ) can be indicative of a positive diagnosis or used as diagnostic indicators for methods and/or kits described herein. In one embodiment, larger numbers of the biomarkers identified herein are used in methods or kits of the invention, since the accuracy of the method or kit may improve as the number of biomarkers screened increases. With respect to aspects of the invention pertaining to evaluating therapeutic efficacy, the methods and kits of the present invention include evaluating whether administration of a therapeutic composition causes a change, either a transient change or a long term change, in one or more of the biomarkers; in two or more of the biomarkers; in three or more of the biomarkers; in four or more of the biomarkers; in five or more of the biomarkers, in six or more of the biomarkers, etc.

[000501 Also envisioned are sets of at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%,

40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the biomarkers listed in any one of the tables presented herein, including Tables lm, 2m, 3, 4H-m, 4H-1, 4H-c, 5c, 6c, 7L, 8L, and 9, wherein the envisioned sets can be indicative of a positive diagnosis or used as diagnostic indicators for methods and/or kits described herein. With respect to aspects of the invention pertaining to evaluating therapeutic efficacy, the methods and kits of the present invention include evaluating whether administration of a therapeutic composition causes a change, either a transient change or a long term change, in a percent of the biomarkers listed in any one of the Tables described herein.

[00051] Representative permutations of biomarkers and/or biomarker signatures are presented herein below for illustrative purposes. Based on the methods described herein, a biological sample isolated from a subject may be determined to exhibit any one of the following biomarker signatures, which are set forth in exemplary fashion, and are not to be viewed as limiting: a+; a-; a+, b+, c+; or a+, b-, c+; wherein "a" = specific protein "a", "b" = specific protein "b", "c" = specific protein "c", etc. and "+" indicates that the protein is present or quantitatively increased relative to subjects without disease, which could be clinically normal or could have a different disease (e.g., a different disease having overlapping clinical symptoms which is, therefore difficult to distinguish) and "-" indicates that the protein is absent or quantitatively decreased relative to subjects without disease, which could be clinically normal or could have a different disease (e.g., a different disease having overlapping clinical symptoms which is, therefore difficult to distinguish).

[00052] For example, the easiest identification of a protein biomarker is the presence of a protein associated with a disease or condition and not with other conditions that might be clinically confused with the disease under consideration. Variations to this scenario include the situation wherein a biomarker is present in an increased quantity or a decreased quantity compared to other conditions or controls. Although not a protein biomarker, an example of this is the presence of glucose in the blood in high quantities in diabetics compared to normal individuals who still have glucose present but not in elevated quantities. Another variation to the first scenario is where the functional biomarker is not just one protein but two or more in combination that can be present or absent or quantitatively different, wherein the ensemble defines its biomarker potential.

[00053] In some embodiments, a biomarker of the invention is a member of a biological pathway. As used herein, the term "precursor" or "successor" refers to molecules that precede or follow the biomarker in the biological pathway. Thus, once a biomarker is identified as a member of one or more biological pathways, the present invention can include additional members of the biological pathway that come before (are upstream of or a precursor of) or follow (are downstream of) the biomarker. Such identification of biological pathways and their members is within the skill of one in the art.

[00054] Also encompassed herein is the analysis of biomarkers identified and listed in the tables presented herein to identify metabolic pathways implicated in the pathogenesis, maintenance, and/or progression of a disease. Such analyses may utilize a variety of software programs, including but not limited to the commercially available Ingenuity Pathway Analysis. Multiple hits in a particular metabolic pathway underscore the potential importance of the pathway for the disease and direct therapeutic intervention toward appropriate modulation of same. Accordingly, the present methods encompass such analyses and the identification of metabolic pathways of potential significance in a particular disease. Knowing that, for example, activation of a metabolic pathway appears to be linked or associated with a particular disease presents the opportunity to test pharmaceutical modulators of the pathway (i.e., inhibitors) to determine if such modulators could be used as therapeutics for treatment of patients with the disease.

[00055] Metabolic pathways may, for example, be associated with several disease conditions based on a quantitative assessment. Examples of pathways that may be markedly involved in one condition and not another or others may also be found. As a specific illustrative example, a comparison of Chronic Fatigue Syndrome (CFS) to Neurologic Post Treatment Lyme disease syndrome (nPTLS), when individual patient samples were analyzed, revealed that four components (CIS, C4B, C1QB, C1QC) associated with activation of the complement cascade were differentially increased in abundance consistently across the nPTLS patients compared to CFS. In another example, a comparison between CFS and nPTLS patiente, looking at the pooled results, revealed that the CDK5 signaling pathway was significantly enriched for proteins identified only in the pooled CFS proteome. This signaling pathway has been linked to Parkinson's (Smith et al. 2003. Proc. Natl. Acad. Sci. 100: 13650) and Alzheimer's diseases (Lew et al. 1994. Nature 371 :423). Another example is related to pathways that are involved in two conditions, that is, common to both but decreased in abundance in the two disease conditions of CFS and nPTLS, compared to normal, but at different levels. Quantitative distinguishing differences could still be found between the two conditions. A specific example relates to networks relevant to neurological function, such as axonal guidance, where the proteins in CFS were further decreased relative to nPTLS.

[00056] Also envisioned are panels of biomarkers comprising at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the biomarkers listed in any one of the tables presented herein, including Tables lm, 2m, 3, 4H-m, 4H-1, 4H-c, 5c, 6c, 7L, 8L, and 9, wherein the envisioned panels can be used to assess a biological sample isolated from a patient to evaluate expression patterns of the biomarkers of the panel, which expression patterns are indicative of a positive diagnosis of a neuropsychiatric disease as described herein. Panels of biomarkers comprising at least one, two, three, and more of the biomarkers listed in any one of Tables lm, 2m, 3, 4H-m, 4H-1, 4H-c, 5c, 6c, 7L, 8L, and 9 (up to the number equivalent to all of the biomarkers in a particular table, including any intervening number, in whole number increments, e.g., 1, 2, 3, 4, 5, 6 . . . ) are also envisioned herein. Any of the indicated panels may also be used to evaluate efficacy of a therapeutic regimen.

[00057] Polypeptide biomarkers may be isolated by any suitable method known in the art.

Native polypeptide biomarkers can be purified from natural sources by standard methods known in the art such as chromatography, centrifugation, differential solubility or immunoassay. In one embodiment, polypeptide and metabolite markers may be isolated from a biological sample using standard techniques known in the art, for example, chromatographic methods or affinity purification using substrate-bound antibodies that specifically bind to the marker. As described herein, immunoaffinity depletion of abundant proteins (with masking potential) enhances coverage and detection of low abundance proteins. As indicated herein above, depletion yields separate fractions that are characterized independently.

[00058] In a positively-associated example, once a protein or peptide is identified (including one lacking name identification, such as a hypothetical protein), a less expensive platform or assay, as compared to mass spectrome ry, can be devised or adapted. The ELISA assay is such an example where an antibody to the biomarker protein/peptide can be used to capture the target biomarker in the biological sample being detected. The sample may be CSF or blood, etc. Variations of this immuno-based technique may also be used such as, but not limited to, Western blots wherein a sample comprising a biomarker is transferred to a membrane and then subsequently allowed to interact with specific antibodies that are coupled to an enzyme (later to be exposed to a substrate that permits colorimetric visualization) or fluorescent material that permit visualization of one or more of the components or subcomponents (such as antigens) of the target biomarker. Alternatively, a non- coupled antibody can be used first and then a second antibody directed to this antibody, which has an enzyme or fluorescent tag attached thereto, can be used in a sandwich-like fashion. Another variation of this protein capturing technique could be multiplexing of several target biomarkers by using beads coated with multiple antibodies such as in the Luminex platform.

[00059] In another embodiment, once a disease protein/peptide biomarker is identified subsequent research may demonstrate that the body of disease subjects makes antibodies to the biomarker or biomarkers and the normal or other disease subject are negative for same. Under such circumstances, the presence of antibodies for a disease protein/peptide biomarker is indicative of disease. Experimentally, the presence of such disease specific antibodies is determined by using the disease protein/peptide biomarker as a binding target for the antibodies. This is a common indirect strategy for detection of infectious disease where the presence of an antibody indicates exposure to a foreign agent and in some cases the rise in titers (quantity of antibodies) over a short period of time indicates a very recent exposure.

[00060] As used herein, a polypeptide is referred to as "isolated" when it has been removed from its natural milieu (i.e., that has been subject to human manipulation), and can include purified polypeptides, partially purified polypeptides, synthetically produced polypeptides, and

recombinantly produced polypeptides, for example. As such, "isolated" does not reflect the extent to which the polypeptide has been purified.

[00061] According to the present invention, the phrase "selectively binds to" refers to the ability of an antibody or antigen binding fragment thereof to preferentially bind to specified proteins. More specifically, the phrase "selectively binds" refers to the specific binding of one protein to another (e.g., an antibody or antigen binding fragment thereof to an antigen), wherein the level of binding, as measured by any standard assay (e.g., an immunoassay), is statistically significantly higher than the background control for the assay. For example, when performing an immunoassay, controls typically include a reaction well/tube that contain antibody or antigen binding fragment alone (i.e., in the absence of antigen), wherein an amount of reactivity (e.g., non-specific binding to the well) by the antibody or antigen binding fragment thereof in the absence of the antigen is considered to be background. Binding can be measured using a variety of methods standard in the art including enzyme immunoassays (e.g., ELISA), immunoblot assays, etc.).

[00062] As used herein, the term "specifically binding," refers to the interaction between binding pairs such as an antibody and an antigen with an affinity constant of at most 10^"6 moles/liter, at most 10^"7 moles/liter, or at most 10^"8 moles/liter.

[00063] The present invention includes the use of any of the biomarkers as described herein

(including genes or their RNA or protein products), as targets for the development or identification of therapeutic compositions and strategies for the treatment of neuropsychiatric diseases, such as for example, multiple sclerosis and/or relapsing multiple sclerosis.

[00064] Methods to measure biomarkers of this invention, include, but are not limited to:

Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, liquid chromatography mass spectrometry (LC-MS), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, microcytometry, microarray, microscopy, fluorescence activated cell sorting (FACS), flow cytometry, laser scanning cytometry, hematology analyzer and assays based on a property of the protein including but not limited to DNA binding, ligand binding, or interaction with other protein partners. More particularly, high throughput, high sensitivity, and high resolution nanocapillary liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS, pre-fractionation (immunoaffinity depletion chromatography) and ultra-high resolution nanocapillary LC separations, high efficiency ion transmission technologies (e.g., electrodynamic ion funnel), and the accurate mass and time (AMT) tag strategy for high-throughput analysis are described herein and known in the art.

[00065] As described herein, the term "probe" is used to refer to an agent that specifically binds to a biomarker listed in one of the tables presented herein. Suitable reagents for binding with a polypeptide corresponding to a biomarker of the invention include antibodies, antibody derivatives, labeled antibodies, antibody fragments,^' and the like. The term "probe" may also be used to refer to an agent that specifically binds to a nucleic acid sequence that encodes a biomarker listed in one of the tables presented herein. Suitable reagents for binding to a nucleic acid (e.g., a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids.

[00066] In accordance with the present disclosure, the tables present information with which an ordinarily skilled practitioner can access the amino acid sequences of the proteins identified herein as biomarkers, as well as nucleic acid sequences encoding same. A stepwise protocol for identification of the amino acid sequences listed in the tables presented herein is as follows: access one of the publicly available databases such as http://www.ebi.ac.uk/IPl IPIhelp.html or

http://www.uniprot.org/ via the internet and enter the IPI number, or the protein name, or the Gene designation. For example, the first protein listed in Table lm is designated "14-3-3 protein epsilon" and the corresponding Gene designation is YWHAE, and IPI designation of IPI00000816.1.

Entering the IPI number, protein name, or Gene into one of the above publicly available databases will reveal the 255 amino acid sequence corresponding to "14-3-3 protein epsilon". The above protocol is a matter of routine practice in laboratories skilled in the art and can be performed for any of the proteins listed therein. Such information may be used to design probes for detection of any of the proteins listed therein or to identify commercially available probes for detection of any of the proteins listed therein. Primers for detection nucleic acid sequences encoding any of the proteins listed in the tables presented herein are also envisioned. Such primers may be used to detect expression or lack thereof of a biomarker or biomarker signature of the invention. The design of primers for detecting expression levels of R A (e.g., mRNA) of a biomarker or biomarkers listed herein is a matter of routine practice with the nucleic acid sequence in hand as provided by publicly available websites such as those mentioned above. Such probes and primers are useful for the kits described herein.

[00067] The present invention also includes a method to diagnose a subject as having a neuropsychiatric disease (e.g., multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme Disease, or one that conventionally may be considered among the differential diagnoses). In one embodiment, the method includes the steps of analyzing a biological sample isolated from the subject to determine if one or more of the biomarkers listed in Tables lm, 3m, or 4H-m is present or if one or more of the biomarkers listed in Table 2m is absent, and diagnosing multiple sclerosis, wherein the presence (Tables lm, 3m, or 4H-m) or absence (Table 2m) of one or more of these biomarkers indicates that the subject has multiple sclerosis. The present invention further encompasses circumstances wherein there is a change in the level/amount of a biomarker of the invention and such a change may also reflect the presence of multiple sclerosis or responsiveness to a therapeutic regimen.

[00068] In another embodiment, the method includes the steps of analyzing a biological sample isolated from the subject to determine if one or more of the biomarkers listed in Table 4H-c, or 5c is present or if one or more of the biomarkers listed in Table 6c is absent, and diagnosing chronic fatigue syndrome, wherein the presence (Table 4H-c or 5c) or absence (Table 6c) of one or more of these biomarkers indicates that the subject has chronic fatigue syndrome. The present invention further encompasses circumstances wherein there is a change in the level/amount of a biomarker of the invention and such a change may also reflect the presence of chronic fatigue syndrome or responsiveness to a therapeutic regimen.

[00069] In a further embodiment, the method includes the steps of analyzing a biological sample isolated from the subject to determine if one or more of the biomarkers listed in Table 7L is present or if one or more of the biomarkers listed in Table 8L is absent (within the limits of detection using methods and assays described herein), and diagnosing Neurologic Lyme Disease, wherein the presence (Table 7L) or absence (Table 8L) of one or more of these biomarkers indicates that the subject has Neurologic Lyme Disease. The present invention further encompasses circumstances wherein there is a change in the level/amount of a biomarker of the invention and such a change may also reflect the presence of Neurologic Lyme Disease or responsiveness to a therapeutic regimen.

[00070] The invention includes a kit for assessing the expression and/or expression levels of at least one of the biomarkers listed in the tables presented herein, whereby detecting the expression and/or expression levels of at least one of the biomarkers in a biological sample isolated from a patient is indicative of a positive diagnosis of the relevant disease to which the table in question pertains (e.g., MS, NLD, or CFS). The kit comprises a plurality of reagents, each of which is capable of binding specifically with a polypeptide (e.g., an antibody) or nucleic acid encoding same corresponding to a biomarker of the invention, e.g., one of the proteins listed in any one of the tables presented herein. Suitable reagents for binding with a polypeptide corresponding to a biomarker of the invention include antibodies, antibody derivatives, labeled antibodies, antibody fragments, and the like. Suitable reagents for binding to a nucleic acid (e.g., a genomic DNA, an mRNA, a spliced mR A, a cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid reagents may include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.

[00071] The kit of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kit may comprise fluids [e.g., phosphate buffered saline (PBS) or SSC buffer] suitable for binding an antibody to a protein for which it is immunologically specific or for annealing complementary nucleic acids, one or more sample compartments, an instructional material which describes performance of a method of the invention, a positive control or controls, such as panel of proteins corresponding one of the panels set forth in any one of the tables presented herein or a biological sample isolated from a normal subject (a subject who does not manifest clinical symptoms of disease), or a biological sample isolated from a patient known to have the disease in questions, and the like.

[00072] The following protocols are provided to facilitate the practice of the present invention.

[00073] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

EXAMPLE I

Materials and Methods

[00074] Cerebrospinal Fluid (CSF) specimens. All specimens had normal clinical laboratory values with respect to microbiology, chemistry (including protein levels), and cell counts (red blood cell were 0-10 / mm³and white blood cells were 0-5/ mm³). Four sets of different types of normal CSF samples were analyzed. The first set, designated as true (healthy) normals was comprised of pooled CSF from 1 1 healthy normal individual volunteers from the United States (8 women and 3 men; aged 24 to 55 years with a median age of 28 years) was used for the

comprehensive analysis using immunoaffinity depletion and 2D-LC -MS/MS. A second set, also true normals included pairs of serial CSF aliquots taken at least 4 weeks apart from 10 healthy volunteers from the United States (age 37-44 years; 5 males and 5 females). A third set, designated as non- neurologic surrogate-normals, was a pool of 200 subjects from Sweden (all without a neurologic or psychiatric disease, most who underwent lumbar puncture for non diagnostic reasons; over 90% were undergoing spinal anesthesia in preparation for orthopedic surgery (e.g. limbs-knees and hips)). Ages ranged from 16 to 65 years with a median of 44 years; 50:50 female:male. They were used in the direct LC-MS analysis using the AMT tag approach. These samples were collected on ice and cells removed by centrifugation [Bergquist et al. (2002) Mass Spectrom Rev 21 : 2-15]. A fourth set, designated as neurologic surrogate-normals consisted of a pool of CSF from 10 people from Sweden with headaches (age 18-35 years; 8 female and 2 male) who had a lumbar puncture to investigate possible CNS infection, and who had normal CSF clinical laboratory values (hence designation surrogate-normal), was collected following the same protocol as the third set and analyzed in the same fashion as the second and third sets of normal CSF. CSF from this group was also subjected to centrifugation to remove cells. CSF from this group was collected following the same protocol as the pool of the 200 non-neurological surrogate-normals. The protein concentrations were determined by Coomassie Plus protein assay (Pierce, Rockford, IL) using a bovine serum albumin standard.

[00075] Immunoaffinity depletion of 14 high-abundance CSF proteins. A total of 18 mL of the pooled CSF sample (from the 1 1 healthy volunteers) was subjected to the separations of 14 high-abundance proteins (albumin, IgG, ooi -antitrypsin, IgA, IgM, transferrin, haptoglobin, ai-acid glycoprotein, a₂-macroglobulin, apolipoprotein A-I, apolipoprotein A-II, fibrinogen, C3 and apolipoprotein B) using a 12.7 x 79.0 mm Seppro^® IgY14 LC10 affinity LC column (Sigma, St Louis, MO) on an Agilent 1 100 series HPLC system (Agilent, Palo Alto, CA), followed the protocols described previously [Liu et al. (2006) Mol Cell Proteomics 5: 2167-2174].

[00076] Protein digestion. The CSF proteins were incubated in 8 M urea and 10 mM dithiothreitol at 37°C for 60 min, followed by alkylation with 40 mM iodoacetamide in the dark for 30 min at room temperature. The samples were diluted 10-fold with 50 mM ammonium bicarbonate (pH 8) and 1 mM CaCl₂, and digested for 3 h at 37 °C using sequencing grade, modified porcine trypsin (Promega, Madison, WI) at a trypsin/protein ratio of 1 :50. Sample cleanup was achieved using a 1-mL SPE C18 column (Supelco, Bellefonte, PA) as described previously [Liu et al. (2006) Mol Cell Proteomics 5: 1899-1913]. The final peptide concentration was determined by BCA assay (Pierce). All tryptic digests were snap frozen in liquid nitrogen and stored at -80 °C.

[00077] Strong cation exchange (SCX) fractionation. For tryptic digests of the IgY14 bound and flow-through fractions (the first set normal CSF pool from BN), 300 μg of tryptic peptides from CSF samples were resuspended in 300 μL· 10 mM ammonium formate, 25% acetonitrile and fractionated by strong cation exchange chromatography as described previously [Liu et al. (2006) Mol Cell Proteomics 5: 1899-1913]. A total of 30 fractions were collected for each sample with each fraction being lyophilized prior to reversed-phase LC-MS/MS analysis.

[00078] Reversed-phase capillary LC-MS/MS and LC-MS analysis. The SCX fractions were analyzed using a custom-built automated four-column high pressure nanocapillary LC system coupled on-line to either a linear ion trap mass spectrometer (LTQ; ThermoFisher) or a linear quadrupole ion trap-orbitrap mass spectrometer (LTQ-Orbitrap, ThermoFisher), both modified in- house with an electrodynamic ion funnel [Shaffer et al. (1997) Rapid Commun Mass Spectrom 11: 1813-1817], via an electrospray ionization interface manufactured in-house. The reversed-phase separation was performed as described previously [Liu et al. (2006) Mol Cell Proteomics 5: 1899- 1913]. To analyze the SCX fractions of the IgY14 bound fraction, the LTQ mass spectrometer was operated in a data-dependent MS/MS mode (m/z 400-2000) in which a full MS scan was followed by 10 MS/MS scans. The ten most intensive precursor ions were dynamically selected in the order of highest intensity to lowest intensity and subjected to collision-induced dissociation using a normalized collision energy setting of 35% and a dynamic exclusion duration of 1 min. The heated capillary was maintained at 200 °C, while the ESI voltage was kept at 2.2 kV. The SCX fractions of the IgY14 flow-through fraction, which are enriched with lower abundance proteins, were analyzed by the LTQ-Orbitrap instrument operated in a data-dependent MS/MS mode with survey full scan MS spectra (m/z 400-2000) acquired in the orbitrap with resolution of 30,000 at m/z 400 (ion accumulation target: 1,000,000), followed by MS/MS of the 10 most intense ions. In the case of label-free quantitation using the unfractionated CSF samples (the second and third set of normal CSF and the headache CSF), the LTQ-Orbitrap MS was operated in the data dependent mode with survey full scan spectra (m/z 400-2000) acquired in the orbitrap with resolution of 60,000 at m/z 400 (accumulation target: 1,000,000). The six most intense ions were sequentially isolated for fragmentation and detection in the linear ion trap.

[00079] Data analysis. The LTQ LC-MS MS raw data were converted into .dta file by

Extract MSn (version 3.0) in Bioworks Cluster 3.2 (Thermo) and the SEQUEST algorithm (version 27 revision 12) was used to independently search all the MS/MS spectra against the human

International Protein Index (IPI) database with a total of 69,731 total protein entries (Version 3.40, released at February 7, 2008). The search parameters used were: 3-Da tolerance for precursor ion masses and 1-Da tolerance for fragment ion masses with no enzyme restraint and a maximum of 2 missed tryptic cleavages. Static carboxyamidomethylation of cysteine and dynamic oxidation of methionine were used during the database search. LTQ-Orbitrap MS/MS data were first processed by an in-house software DeconMSn [Mayampurath et al. (2008) Bioinformatics 24: 1021-1023] to accurately determine the monoisotopic mass and charge state of parent ions, followed by SEQUEST search against the IPI database in the same fashion, except that 0.1 -Da tolerance for precursor ion masses and 1-Da tolerance for fragment ion masses were used. A set of criteria considering the cross correlation score (Xcorr) and delta correlation (ACn) values along with tryptic cleavage and charge states were developed using the decoy database approach and applied for filtering the raw data to limit false positive identifications to <1% at the peptide level [Peng et al. (2003) J Proteome Res 2: 43-50; Elias et al. (2007) Nat Methods 4: 207-214; Qian et al. (2005) J Proteome Res 4: 53- 62]. For the LTQ-Orbitrap data, the distribution of mass deviation (from the theoretical masses) was first determined as having a standard deviation (σ) of 2.05 part per million (ppm), and peptide identifications with mass error of greater than 3σ were filtered out. In general, slightly lower Xcorr cutoff values were used when combined with ACn and the mass error constraint to achieve the same level of false positive rate (<1%). For peptides identified by both LTQ-Orbitrap (IgY14 flow- through fraction) and LTQ (IgY14 bound fraction) analyses, the database matching scores are shown only for the LTQ-Orbitrap analysis, along with their mass errors.

[00080] The AMT tag strategy [Smith et al. (2002) Proteomics 2: 513-523] was used for identifying and quantifying LC-MS features measured by LTQ-Orbitrap. The filtered MS/MS peptide identifications obtained from the LTQ and LTQ-Orbitrap analyses of CSF samples were included in an AMT tag database with their theoretical mass and normalized elution time (NET; from 0 to 1) recorded. LC-MS datasets were then analyzed by in-house software VIPER [Monroe et al. (2007) Bioinformatics 23: 20^'21-202^'3] that detects features in mass-NET space and assigned them to peptides in the AMT tag database [Zimmer et al. (2006) Mass Spectrom Rev 25: 450-482]. A 1 1-Da shift strategy analogous to the decoy database approach used for LC-MS/MS identification of peptides was applied for estimating the false discovery rate of the AMT analysis as previously described [Petyuk et al. (2007) Genome Res 17: 328-336]. A false positive rate of <4% was estimated for each of the LC-MS data sets. The resulting lists of peptides from 2D-LC-MS/MS or direct LC-MS analysis was further analyzed by ProteinProphet software [Nesvizhskii et al. (2003) Anal Chem 75: 4646-4658] to remove redundancy in protein identification as described previously [Liu et al. (2006) Mol Cell Proteomics 5: 1899-1913].

[00081] Data normalization and quantification of the changes in protein abundance between the normal and headache CSF samples were performed and visualized using in-house software DAnTE [Polpitiya et al. (2008) Bioinformatics 24: 1556-1558]. Briefly, peptide intensities from the LC-MS analyses were log2 transformed and normalized using a mean central tendency procedure. Peptide abundances were then "rolled up" to the protein level employing the R-rollup method (based on trends observed at peptide level) implemented in DAnTE. ANOVA and clustering analyses were also performed using DAnTE. Gene ontology annotation was performed using a software tool STRAP [Bhatia et al. (2009) Anal Chem 81 : 9819-9823]. The final distribution charts were generated using Excel.

Results

[00082] A comprehensive analysis of the CSF proteome from healthy normal individuals is described herein and presents the foundation for future investigation on this biological fluid which may be highly reflective of the status of the brain and central nervous system. The results described herein make available a comprehensive coverage of CSF proteins from normal healthy individuals. From the pool of 1 1 CSF samples from healthy volunteers, the present inventors identified with high confidence a total of 19,051 tryptic peptides, covering 2630 non-redundant proteins, with 1506 having at least two peptide identifications. The immunoaffinity-based partitioning generated a separate bound fraction consisting of the 14 most abundant proteins and their potential associated proteins, and a flow-through fraction enriched with the less abundant proteins in CSF. Similar to plasma, the bound fraction represents approximately 95% of the total protein mass. Both fractions were subjected to 2D-LC-MS/MS analysis.

[00083] The set of 2630 CSF proteins, and a comprehensive set of 3654 proteins from our previous plasma database [Liu et al. (2006) Mol Cell Proteomics 5: 1899-1913], showed very similar distribution of gene ontology terms in biological process and molecular function, but different distributions with respect to cellular component: a total of approximately 35% of the CSF proteins are from plasma membrane, cell surface or extracellular space, while blood plasma has a total of 28% of proteins in those three categories; there are also fewer CSF proteins derived from the nucleus and cytoplasm (10% versus 15% and 1 1% versus 16%, respectively. Importantly, nearly 56% of the proteins are CSF-specific and are not present in our larger plasma database of 3654 proteins, also analyzed by LC-MS/MS. This is notable because the acquisition and analysis conditions likely favored the set of plasma proteins as opposed to the CSF proteins. This is because more proteins were likely available for detection in the plasma of burn patients due to severe tissue leakage, and there was the additional dimension of sample fractionation via enrichment of cysteinyl and N-linked glycopeptides. It is noteworthy that this cannot be viewed as a head-to-head comparison in light of the differences in sample type and conditions, extensiveness of fractionation and MS

instrumentation.

[00084] Comparison between proteins detected in this study and those (which we have termed neurologic surrogate-normals) from the CSF study by Zougman et al., reveals a 92% overlap (see Figure 1.

[00085] In order to assess the CSF protein variability from serial sample collections, the present inventors examined individual (non-pooled) samples from another group of 10 healthy volunteers (5 male, 5 female; age range 37-44 years old) who had two CSF samples obtained at least 4 weeks apart using the AMT tag approach. Inter-subject differences were far greater than intra- subject differences. Statistical tests of variance of differences (ANOVA) were performed for these data sets based on different factors (e.g., subject, gender, and time of sampling), followed by unsupervised hierarchical clustering analysis of the statistically significant proteins (p-value <0.01). It is clear that human heterogeneity is the major factor responsible for inter-sample differences; clustering of the "significant" proteins could not distinguish corresponding groups based on the other factors defined in the ANOVA analysis^' (i.e., gender and time of sampling), except for "subject" (i.e., normal volunteers).

[00086] As an example of how CSF proteomic databases may be used to better understand disease states, the present inventors compared the proteomes of two similarly processed (see

Methods) pooled samples of patients using the mass spectrometry strategy [Smith et al. (2002) Proteomics 2: 513-523]. The first set, considered as neurologic surrogate-normals was a pool of 10 headache patients. CSF had been obtained to evaluate the possibility of a CNS infection or bleed but all clinical results were normal. The second set, considered as non-neurologic surrogate-normals, was a pool of 200 subjects (without a neurologic disease, who underwent lumbar puncture for non diagnostic reasons; over 90% were undergoing spinal anesthesia in preparation for orthopedic surgery (limbs-knees and hips)). Significantly distinct results were found between each group.

Specifically, 191 ± 7 and 211 + 8 non-redundant proteins were identified from the 3 replicates of each data set. Statistical analysis comparing these CSF data sets showed that the neurologic surrogate- normal CSF pool had distinctive quantitative differences compared to the non-neurologic surrogate normal pool (22 proteins with p-value <0.01 by ANOVA). Unsupervised hierarchical clustering of abundances of all proteins clearly separates these two groups. One interesting difference was the identification and quantification of certain hemoglobin isoforms, which were among significantly changed proteins identified by the statistical analysis, in the neurologic surrogate-normal (headache) samples. Although Zougman et al. [(2008) J Proteome Res 7: 386-399] previously identified these same proteins in a qualitative analysis of their neurologic surrogate-normal samples, the present study reveals that these isoforms were increased by about ten-fold on average. The differences found in the present study suggest that it would be attractive to extend these studies with immunoaffinity depletion applied to different defined categories of headache subjects.

Summary

[00087] The present study provides the most comprehensive CSF protein coverage and list reported to date for healthy normal individuals including serial lumbar punctures. [Schutzer et al. (2010) Establishing the Proteome of Normal Human Cerebrospinal Fluid, PLoS One 5(6): el0980]. The protein set has immediate utility for investigators interested in using CSF to study neurological or psychiatric diseases. As evidenced in Examples II-IV, it serves as a normative base to which disease states may be compared. The present study also suggests that CSF protein variability over a short time may be relatively limited in an individual and thus functionally useful.

[00088] The other major previous investigations of CSF from healthy individuals were published by Zhang et al. [(2005) Neurobiol Aging 26: 207-227] and updated by part of that group, Xu et al. [(2006) Int Rev Neurobiol 73: 29-98]. What began as detection of approximately 315 proteins was expanded to 915 using different mass spectrometry methods. Interestingly Xu et al. [(2006) Int Rev Neurobiol 73: 29-98] stated that they believed their coverage of the normal CSF was insufficient because they were unable to detect two well known CSF proteins, a-synuclein [Yuan et al. (2005) Proteomics 5: 541-550] and gelsolin [Yuan et al. (2002) Electrophoresis 23: 1 185-1196]. The present methods and approach differed from these references, and included a rigorous separation of abundant from less abundant proteins to mitigate the masking effect of the most abundant proteins, as well as high-resolution LC coupled to MS/MS analysis for highly efficient peptide identification. The present inventors did identified 2630 proteins in total, including a-synuclein and gelsolin.

[00089] Due to the challenge in obtaining CSF from healthy people, most previous studies may have used CSF from "surrogate-normals," that is CSF collected from people with neurological complaints such as headache but with normal clinical CSF laboratory values. As described herein, the present inventors compared proteomes of two different surrogate-normal groups. Significant differences were noted between the two groups. Accordingly, this study supports the potential usefulness of the "true" normal human CSF proteome data library as an invaluable tool in investigating

pathophysiological abnormalities in neurological and psychiatric disorders.

[00090] Proteomic databases can be used in several ways. The present inventors' perspective with regard to using these proteomic databases for studying diseases involves a stepwise strategy. The first step is a comparison of pooled samples representative of the disease to normal subjects or a comparator disease. The second step involves the selection of specific candidate proteins. The selection of candidate proteins is not likely to be predicted in advance and may require bioinformatic strategies and knowledge related to the disease under study. A third step would involve analysis of the individual samples contributing to the pool to ascertain how many of the samples actually contained one or more of the candidate proteins. This step provides a check in the event that a single individual in the pool disproportionately contributes a protein compared to other subjects. The results would be subjected to statistical analyses in accordance with standard practice. In the case of a search for biomarker proteins, an objective is to select those that meet clinically useful criteria, such as presence, absence or relative abundance in a large percentage of disease subjects and not so in most subjects without the disease under consideration. The fourth step would involve verification of the previous results using independent individual samples with the same disease. A final validation step may involve analyzing a larger number of subjects with the disease and controls using assays targeted to the candidate proteins. In contrast to the discovery phases, it would be advantageous, if feasible, to use assay platforms already having wide clinical use. Immunobased assays such as ELISA and Western blots may serve this purpose being relatively inexpensive. Steps 3 and 4 will likely employ a type of mass spectrometry which targets selected candidate proteins, such as Multiple Reaction Monitoring (MRM) using triple quadrupole instrumentation.

[00091] The availability of the data presented here, detailing the normal human CSF proteome, should prove to be a critical base on which to compare proteins, both qualitatively and quantitatively, in studies of patients with a variety of neurological or psychiatric diseases.

EXAMPLE II

Multiple Sclerosis

[00092] In the experimental analysis of data on documented first attack Multiple Sclerosis subjects, long lists of proteins found in these subjects (data not shown) and small subset lists as well as a list of those proteins that appear to be absent (below the level of detection) have been found. Specifically:

[00093] 1) Table lm shows Cerebrospinal Fluid (CSF) Proteins present only in Multiple

Sclerosis patients compared to Surrogate Non-Neurologic Normals and to Surrogate Neurologic Normals

(Headaches). This is a Qualitative List of CSF Proteins Present in the Pooled First Attack Multiple Sclerosis Patients compared to the combined lists of Proteins Found in a Similarly Analyzed Group of Non-neurologic Surrogate Normal Subjects and Proteins Found in Neurologic Surrogate-Normals (Headache subjects with normal CSF clinical laboratory values).

[00094] 2) Table 2m shows a Qualitative List of CSF Proteins Absent only in the Pooled First

Attack Multiple Sclerosis Patients compared to the combined lists of a) Proteins Found in a similarly Analyzed Group of Non-neurologic Surrogate Normal Subjects (both groups analyzed without immunoaffinity depletion of most abundant proteins) and b) Proteins Found in an expanded list of True Normals (where immunoaffinity depletion was applied).

[00095] 3) Table 3m shows a subset of CSF Proteins Present In Multiple Sclerosis not in combined lists of proteins from Normals or Headaches (immunoaffinity depletion was not applied)

[00096] 4) Table 4H-m shows identified CSF proteins in first attack Multiple Sclerosis that have high potential to be candidate biomarkers because their function is not known and they remain unknown (referred to as a hypothetical or uncharacterized protein).

EXAMPLE III

Chronic Fatigue Syndrome

[00097] In the experimental analysis of data on Chronic Fatigue Syndrome subjects, long lists of proteins were found in these subjects and smaller subset lists as well as a list of those proteins that appear to be absent (below the level of detection). Immunoaffinity depletion of abundant proteins was applied in the analyses. In addition, semi-quantitative, or relative protein abundance

comparisons were made to proteins found in a disease that has common features with Lyme disease- Chronic Fatigue Syndrome. Also found were proteins associated with this group that are considered hypothetical or uncharacterized proteins.

Specifically:

[00098] 1) Table 4H-c shows the list by IPI number of those hypothetical or uncharacterized proteins that were found in Chronic Fatigue Syndrome.

[00099] 2) Table 5c shows the CSF Proteins Present in Chronic Fatigue and not in Normals or Neurologic Lyme subjects. All had immunoaffinity depletion. They are listed by IPI identification numbers representing 738 CSF Proteins.

[000100] 3) Table 6c shows the CSF Proteins Absent in Chronic Fatigue but Present in Neurologic Lyme or Normals.

[000101] 4) Table 9 shows the Quantitative Relative Abundance of CSF Proteins in Chronic Fatigue compared to Neurologic Lyme Disease. A ratio greater than 1 indicates there is a relative quantitative difference in Chronic Fatigue compared to Neurologic Lyme disease. Ratios near 1 suggest equal relative abundances. Ratios less than 1 indicate that the protein is present in a greater relative abundance in Neurologic Lyme disease compared to Chronic Fatigue. There are 168 proteins in Chronic Fatigue that are 2 fold greater in relative abundance than those proteins Neurologic Lyme disease. There are 1081 proteins that are relatively more abundant in Neurologic Lyme disease compared to Chronic Fatigue with a ratio of 0.5 or less. Blank cell is close to 0 ratio.

EXAMPLE IV

Neurologic Lyme Disease

[000102] In the experimental analysis of data on documented Neurologic Lyme disease subjects, long lists of proteins were found in these subjects and smaller subset lists as well as a list of those proteins that appear to be absent (below the level of detection). Immunoaffinity depletion of abundant proteins was applied in the analyses. In addition, semi-quantitative, or relative protein abundance comparisons were made to proteins found in a disease that has common features with Lyme disease- Chronic Fatigue Syndrome. Also found were proteins associated with this group that are considered hypothetical or uncharacterized proteins.

Specifically:

[000103] 1 ) Table 4H-L shows the list of by IPI number of those hypothetical or

uncharacterized proteins that were found in Neurologic Lyme disease.

[000104] 2) Table 7 L shows the Qualitative List of CSF Proteins Identified (Present) in Patients with Neurologic Lyme disease and not found in True Normals or Chronic Fatigue. All with immunoaffinity depletion. There are 692 proteins in this list.

[000105] 3) Table 8 L shows the CSF Proteins Absent in Neurologic Lyme disease but Present in Normals or Chronic Fatigue subjects. There are 1597 Proteins in this list.

[000106] 4) Table 9 shows the Quantitative Relative Abundance of CSF Proteins in Chronic Fatigue compared to Neurologic Lyme Disease. A ratio greater than 1 indicates there is a relative quantitative difference in Chronic Fatigue compared to Neurologic Lyme disease. Ratios near 1 suggest equal relative abundances. Ratios less than 1 indicate the protein is present in a greater relative abundance in Neurologic Lyme disease compared to Chronic Fatigue. There are 168 proteins in Chronic Fatigue that are 2 fold greater in relative abundance than those proteins Neurologic Lyme disease. There are 1081 proteins that are relatively more abundant in Neurologic Lyme disease compared to Chronic Fatigue with a ratio of 0.5 or less. Blank cell is close to 0 ratio) [000107] While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

Table lm. Cerebrospinal Fluid (CSF) Proteins present only in Multiple Sclerosis patients compared to Surrogate Non-Neurologic Normals AND Surrogate Neurologic Normals (Headaches): Qualitative List of CSF Proteins Present in the Pooled First Attack Multiple Sclerosis Patients compared to the combined lists of Proteins Found in a Similarly Analyzed Group of Non-neurologic Surrogate Normal Subjects and Proteins Found in Neurologic Surrogate- Normals (Headaches subjects with normal CSF clinical laboratory values). IAD = immunoaffinity depletion

CSF Proteins Present In MS not

IPI:IPI00298547.3 Protein DJ-1 PAR 7

IPI:IPI00298793.4 Beta-mannosidase precursor MANBA

IPI:IPI00329688.2 Protein YIPF3 YIPF3

Isoform 1 of Receptor-type tyrosine-protein phosphatase N2

IPI:IPI00334666.2 precursor PTPRN2

IPI:IPI00337548.5 Cell growth regulator with EF hand domain protein 1 CGREF1

IPI.IPI00376394.4 Sulfhydryl oxidase 2 precursor

IPI:IPI00382426.1 Ig lambda chain V-H region TRO

ΪΡΙ:ΙΡΙ00382447.1 Ig lambda chain V-VI region AR

IPI:IPI00382476.1 Ig heavy chain V-III region WEA

IPI:IPI00382482.1 Ig heavy chain V-III region CAM

IPI:IPI00382490.1 Ig heavy chain V-III region BUR

Myosin-reactive immunoglobulin kappa chain variable region

IPI:IPI00384402.1 (Fragment)

ΪΡΪ:ΪΡίθ0385143.1 Microfibrillar protein 2 (Fragment)

IPI:IPI00386131.1 Ig kappa chain V-III region IARC/BL41 precursor

IPI:IPI00387096.1 Ig kappa chain V-I region Kue

ΙΡΙ:ΙΡΪ0038710Ϊ.1 Ig kappa chain V-I region Sew

IPI:IPI003871 13.1 Ig kappa chain V-III region B6

IPI:IPI00419442.3 IGLV6-57 protein IGLV6-57

IPI:IPI00455667.5 hypothetical protein LOC402665 LOC402665

IPI:IPI00465255.6 Isoform 1 of Proline-rich acidic protein 1 precursor PRAP1

IPI:IPI00748265.2 Rheumatoid factor RF-ET13

IPI:IPI00816737.1 Rheumatoid factor D5 heavy chain (Fragment)

IPI:IPI00829810.1 Uncharacterized protein ENSP00000375027

IPI:IPI00854624.1 Uncharacterized protein ENSP00000375043

IPI:IPI00854745.1 Uncharacterized protein ENSP00000375019

Table 2m. Qualitative List of CSF Proteins Absent only in the Pooled First Attack Multiple Sclerosis Patients compared to the combined lists of a) Proteins Found in a similarly Analyzed Group of Non-neurologic Surrogate Normal Subjects (both groups analyzed without

immunoaffinity depletion (IAD) of most abundant proteins) and b) Proteins Found in an expanded list of True Normals (where immunoaffinity depletion was applied).

MinOfORF=Non redundant IPI designation

Table 3m. A subset table of Table 1 illustrating those CSF proteins identified that have high potential as candidate biomarkers.

MinOfORF = Non redundant IPI designation

IAD = Immunoaffinity depletion

MinOfORF CSF Proteins Present In Multiple Sclerosis not in combined

lists of proteins from Normals or Headaches (no IAD) GENE

IPI:IPI00001516.1 Isoform Long of Protocadherin alpha C2 precursor PCDHAC2 IPI:IPI00026569.3 HLA class I histocompatibility antigen, A- 1 alpha chain precursor HLA-A IPI:IPI00382426.1 Ig lambda chain V-II region TRO

IPI:IPI00382447.I Ig lambda chain V-VI region AR

IPI:IPI00382490.1 Ig heavy chain V-III region BUR

IPI:IPI00829810.1 Uncharacterized protein ENSP00000375027

IPI:IPI00854624.1 Uncharacterized protein ENSP00000375043

IPI:IPI00854745.1 Uncharacterized protein ENSP00000375019

Table 4H. This Table is divided into 3. The tables show identified CSF proteins that have high potential to be candidate biomarkers because their function is not known and they remain unknown (referred to as a hypothetical or uncharacterized protein).

Table 4H-m is a subset of Table 1 and Table 3 containing those hypothetical/uncharacterized CSF proteins identified in Multiple Sclerosis

IAD= Immunoaffinity depletion

MinOfORF=Non redundant IPI designation

Table 4H-1 Hypothetical proteins found in neurologic Post Treatment Lyme Disease

IPI

IPI00166766 IPI00852979

IPI00443799 IPI00374914

IPI00554474 IPI00003269

IPI00455667 IPI00749328

IPI00414294 IPI00644752

IPI00166465 1PI00749338

IPI00328872 IPI00794307

IPI00181279 1PI00847409

IPI00644840 IPI00411480

IPI00848252 1P100739387

IPI00847373 IPI00855747

IPI00186004 IPI00384971

IPI00395010 IPI00061520

IPI00400986 IPI00006556

IPI00795992

Table 4H-c

Hypothetical proteins detected in Chronic fatigue

IPI

IPI00003269

IPI00006556

1PI00061520

IPI00166766

IPI00168255

IPI00176210

IP100328872

IPI00374223

IPI00374914

IPI00395010

IPI00396025

IPI00398586

IPI00400986

IPI00413868

IPI00414294

IPI00418966

IPI00419675

IPI00443799

IPI00455667

IPI00550862

IPI00554474

IPI00644752

IPI00749328

IPI00789889

IPI00807406

IPI00852979

Table 5c 1

Table 5c 2

Table 5c 3

Table 5c 4

Table 5c 6

Table 5c 7

Table 5c 8

Table 5c 9

Table 5c 10

Table 5c 11

Table 5c 12

Table 5c 13

Table 5c 14

Table 5c 15

Table 5c 16

Table 5c 17

Table 5c 18

Table 5c 19

Table 5c 20

Table 5c 21

Table 5c 22

Table 5c 23

Table 5c 24

Table 6c 1

Table 6c. CSF Proteins Absent in Chronic Fatigue but Present in Neurologic Lyme or Normals

CleanlPI Protein Gene

IPIOO 160369 PRKCA-binding protein PICKl

IP100289862 Secernin-1 SCRN1

IPI00002478 Isoform B of Endothelin-converting enzyme 1 ECE1

IPI00027438 Flotillin-1 FLOT1

IPI00852669 Zinc finger protein 516 Z F516

IPI00017297 Matrin-3 MATR3

IPI00642645 Methylenetetrahydrofolate reductase MTHFR

IPI00470812 Putative uncharacterized protein DKFZp781E21 107 LOC339977

IPI00556381 Putative uncharacterized protein (Fragment) TRIM 16

IPI00004569 Isoform MZF1 A of Myeloid zinc finger 1 MZF1

IPI00240059 Transmembrane and coiled-coil domains protein 3 TMCC3

IPI00022361 Band 3 anion transport protein SLC4A1

IPI00017964 Small nuclear ribonucleoprotein Sm D3 SNRPD3

IPI00478640 Isoform 1 of Transmembrane protein C17orf87 C17orf87

IPI00013290 hepatoma-derived growth factor-related protein 2 isoform 1 HDGF2

IPI0001 1051 T-cell leukemia homeobox protein 1 TLX1

IPI00004838 Isoform Crk-II of Proto-oncogene C-crk CRK

IPIOO 154858 Platelet endothelial aggregation receptor 1 precursor PEAR1

IPI00748733 Similar to Slit homolog 3 protein precursor -

IPI00023919 26S protease regulatory subunit 8 PSMC5

IPI00830051 Similar to Immunolgoobulin heavy chain LOC90925

Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32

IPI00007423 family member B ANP32B

IPI00553215 V 1 -5 protein IGLV2-18

IPI00020005 Arylsulfatase E precursor ARSE

IPI00550720 Isoform 1 of Uncharacterized protein CI 9orf57 C19orf57

IPIOO 103510 Relaxin receptor 2 RXFP2

IPI00373872 polycystin 1-like 2 isoform a PKD1L2

IPI00015181 Integrin alpha-9 precursor ITGA9

IPI00013945 Isoform 1 of Uromodulin precursor UMOD

IPI00295172 Ninjurin-1 NINJ1

IPI00328522 TEL motif-containing protein 1 TELC1

IPI0000081 1 Proteasome subunit beta type-6 precursor PSMB6

IPI00847415 Isoform 4 of Dual specificity protein kinase CL 3 CL 3

IPI00251596 Isoform 1 of Collagen alpha- 1 (XXIII) chain COL23A1

IPI00550906 Cleavage stimulation factor 64 kDa subunit, tau variant CSTF2T

IPI00550263 Isoform 5 of Serine/threonine-protein kinase MRCK alpha CDC42BPA

IPI00045219 Sorting nexin-18 SNAG1

IPI00063245 Uncharacterized protein FUBP3 FUBP3

IPI00221235 nucleoporin 160kDa NUP160

IPIOO 167560 PAP-associated domain-containing protein 4 PAPD4

IPI00005719 Isoform 1 of Ras-related protein Rab- 1 A RABIA

IPIOOO 13933 Isoform DPI of Desmoplakin DSP Table 6c 2

Table 6c 3

Isoform 1 of 3-hydroxy-3-methylglutaryl-coenzyme A

IPI00021770 reductase HMGCR

IPI00465045 D1P2 disco-interacting protein 2 homolog B DIP2B

IPI00004509 Leukotriene C4 synthase LTC4S

IPI00018803 homeobox D12 HOXD12

IPI00884371 Uncharacterized protein ENSP00000383215 -

IPI00002881 Bcl-2-related protein Al BCL2A1

Isoform 1 of Glycosylphosphatidylinositol anchor

1P100021594 attachment 1 protein GPAA 1

IPIO0010360 Isoform 1 of Collagen alpha-3(IV) chain precursor COL4A3

IPI00022890 Ig lambda chain V region 4A precursor IGLV7-43

IPI00219468 Isoform Ila of Profilin-2 PFN2

Isoform 1 of Uncharacterized serine/threonine-protein

IPI00065352 kinase Sg 494 FLJ25006

IPI00000388 Zinc finger protein 175 ZNF 175

IPI00017163 Isoform 1 of E3 ubiquitin-protein ligase HECW2 HECW2

IPI00465044 Protein RCC2 RCC2

Cytochrome b-cl complex subunit 1, mitochondrial

IPI00013847 precursor UQCRC1

IPI00394807 Regenerating islet-derived protein 3 gamma precursor REG3G

IPI00024248 Sodium/iodide cotransporter SLC5A5

IPI00022830 Isoform 2 of NSFL1 cofactor p47 NSFL1C

IPI00026665 Glutaminyl-tRNA synthetase QARS

IPI00180386 Isoform GN-1 L of Glycogenin-1 GYG1

IPI00465345 Isoform 3 of Pre-mRNA-processing factor 40 homolog B PRPF40B

IPI00065388 Isoform 1 of Coiled-coil domain-containing protein 17 CCDC17

IPI00289540 Isoform 2 of Usherin precursor USH2A

IPI00748216 CD A FLJ20187 fis, clone COLF0433 GTF3C5

IPI00167638 Isoform 1 of GTP-binding protein 10 GTPBP10

Isoform 1 of Mannan-binding lectin serine protease 2

IPI00294713 precursor MASP2

IPI00022143 Isoform 1 of Extended-synaptotagmin-1 FAM62A

IPI00023663 Putative transcription factor Ovo-like 1 OVOL1

IPI00003406 Isoform 1 of Drebrin DBN 1

IPI00015602 Mitochondrial precursor proteins import receptor TOMM70A

1PI00072377 Isoform 1 of Protein SET SET

cAMP-dependent protein kinase type II-beta regulatory

IPI00554752 subunit PRKAR2B

Glycine cleavage system H protein, mitochondrial

IPI0001 1604 precursor GCSH;LOC730107

IPI00401586 Chromosome 18 open reading frame 62 C 18orf62

2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial

IPI00026492 precursor GCAT

IPI00384861 Isoform 1 of ARF GTPase-activating protein GIT1 GIT1

IPI00644529 Isoform 2 of Zinc finger protein 615 ZNF615

IPI00028880 Putative DNA polymerase POLN

IPI00020008 NEDD8 precursor NEDD8

Isoform 1 of FRAS 1 -related extracellular matrix protein 2

IP100180707 precursor FREM2

IPI00014878 Uncharacterized protein PRKD1 PRKD1

IPI00794791 Isoform 2 of IQ domain-containing protein D IOCD Table 6c 4

Table 6c 5

Isoform 1 of Membrane-associated phosphatidylinositol

IPI00307757 transfer protein 3 PITPNM3

Zinc-binding alcohol dehydrogenase domain-containing

IPIOO 166738 protein 2 ZADH2

IPI00399252 Isoform 1 of Protein Jade-1 PHF17

IPI00412977 Prothymosin alpha -

IPI00396077 Isoform 1 of E3 ubiquitin-protein ligase Topors TOPORS

Human immunodeficiency virus type I enhancer-binding

IPIOO 144243 protein 2 HIVEP2

IPI00446355 CD A FLJ41803 fis, clone NHNPC2002749 IER5L

IPIOO 167861 Protein SMG5 SMG5

IPI00005530 FMRPamide-related peptides precursor NPVF

IPIOO 186004 hypothetical protein LOC57730 IAA1641

Isoform 1 of Vacuolar proton translocating ATPase 1 16

IPI00465178 kDa subunit a isoform 1 ATP6V0A1

Radical S-adenosyl methionine domain-containing protein

IPI00291463 2 RSAD2

IPI00472171 RPL7 protein RPL7

Isoform 2 of MAP kinase-interacting serine/threonine-

IPIOO 187091 protein kinase 1 M NK1

IPI00398421 Isoform 1 of Potassium channel subfamily T member 2 KCNT2

IPI00007040 Zinc finger protein 222 ZNF222

IPI00220578 Guanine nucleotide-binding protein G GNAI3

IPI00740191 similar to Forkhead box protein LI LOC651986

IPI00044607 Protein phosphatase inhibitor 2-like protein 1 PPP1R2P1

IPI00301923 Isoform 1 of Cell division protein kinase 9 CDK9

IPI00255145 hypothetical protein LOC342346

IPI00022228 Vigilin HDLBP

IPI00010737 Thrombomodulin precursor THBD

IPI00059395 inesin-like protein IFC2 KIFC2

IPI00030319 Forkhead box protein F2 FOXF2

Isoform 1 of Myeloid/lymphoid or mixed-lineage leukemia

IPIOO 168806 protein 3 homolog MLL3

IPIOOO 18275 Prion-like protein doppel precursor PRND

IPI00216704 Isoform 2 of Spectrin beta chain, erythrocyte SPTB

IPI00034277 Isoform A of Probable cation-transporting ATPase 13A1 ATP13A1

IPIOOO 15285 Ethanolamine-phosphate cytidylyltransferase PCYT2

IPIOO 152853 Isoform 1 of Phostensin KIAA 1949

IPI00302850 Small nuclear ribonucleoprotein Sm Dl SNRPD1

IPI00478124 61 kDa protein UCKL1

N-terminally extended type 3 canonical transient receptor

IPIOOO 13681 potential channel TRPC3

IPI00446785 CDNA FLJ41 1 16 fis, clone BRACE 1000572 -

IPI00784272 Putative uncharacterized protein -

IPI00293460 ATP-binding cassette sub-family A member 1 ABCA1

IPIOOO 19208 Similar to 60S ribosomal protein L29 -

IPI00304596 Non-POU domain-containing octamer-binding protein NONO

IPI0041 1452 Uncharacterized protein DOCK1 1 DOCK 1 1

IPI00444395 CDNA FLJ45615 fis, clone BRTHA3026180 -

IPIOOO 19278 Thiamine transporter 2 SLC19A3

IPIOOO 12895 Isoform 1 of Carbonic anhydrase 12 precursor CA12 Table 6c 6

Table 6c 7

Table 6c 8

Table 6c 9

IPI00021347 Ubiquitin-conjugating enzyme E2 L3 UBE2L3

Isoform CD6A of T-cell differentiation antigen CD6

IPI00025700 precursor CD6

IPI00061507 Isoform 3 of Ester hyflrolase C I l orf54 Cl lorf54

IPI00000270 Ribonuclease 7 precursor RNASE7

Isoform 2 of Complement C lq tumor necrosis factor-

IPI00479430 related protein 9 precursor C 1 QT F9

Isoform 2 of Cysteine-rich with EGF-like domain protein 2

IPI00386754 precursor CRELD2

Isoform 4 of Electrogenic sodium bicarbonate cotransporter

IPI00016949 1 SLC4A4

IPI00031547 Desmoglein-3 precursor DSG3

IPI00382756 Isoform 2 of Pleiotropic regulator 1 PLRG1

Transmembrane emp24 domain-containing protein 3

IPI00604599 precursor TMED3

IPI00296798 Isoform 1 of Fibrinogen C domain-containing protein 1 FIBCDl

IPI00743284 Methionine synthase MTR

IP100021363 Histone demethylase J ARID 1 A JARID1A

IPI00749440 Uncharacterized protein ENSP00000368180 -

IPI00216683 M-phase inducer phosphatase 3 CDC25C microtubule associated monoxygenase, calponin and LIM

IPI00737969 domain containing 3 MICAL3

IPI00015522 Growth/differentiation factor 5 precursor GDF5

IPI00877084 Isoform 1 of Coiled-coil domain-containing protein 144C CCDC144C

IPI00060265 Zinc finger protein 775 ZNF775

1PI00171 199 Isoform 2 of Proteasome subunit ajpha type-3 PSMA3

IPI00003483 Isoform 1 of Neuralized-like protein 1 NEURL

IPI00024802 TATA-binding protein-associated factor 172 BTAF1

IPI00374039 Conserved hypothetical protein Clorfl 89

IPI00419575 Protein of unknown function DUF410 family protein C7orf20

IPI00019090 Collagen alpha- 1 COL19A1

IPI0001 1756 Homeobox protein Meisl MEIS1

IPI00021834 Isoform Alpha of Tissue factor pathway inhibitor precursor TFPI

IPIOO 167254 Isoform 4 of Inactive phospholipase D5 PLD5

IPI00442121 delta-aminolevulinic acid dehydratase isoform a ALAD

IPI00013455 CLIP l protein CLIPl

IPI00026299 Isoform Glycophorin C of Glycophorin-C GYPC

IPIOOO 12687 27 kDa protein C l orf83

IPI00845508 BAH domain and coiled-coil containing 1 BAHCC1

Isoform 1 of Pre-B-cell leukemia transcription factor-

IPI00332106 interacting protein 1 PBXIP1

IPI00418426 Metal transporter CN M4 CN M4

IPI00002524 ATP-sensitive inward rectifier potassium channel 14 KCNJ14

IP100745300 31 kDa protein NAT1 1

IPI000001 10 Zinc finger protein 337 ZNF337

IPI00009148 Diphosphoinositol polyphosphate phosphohydrolase 1 NUDT3

IPI00297767 Casein kinase I isoform gamma-2 CSN 1G2 ,

IPIOO 186826 Ephrin receptor EPHB4

IPI00787932 similar to zinc finger protein 10 hCG 1646157 Table 6c 10

Table 6c 1 1

Table 6c 12

Table 6c 13

Table 6c 14

IPI00009804 DNA-binding protein SATB 1 SATB1

Isoform 1 of UDP-GlcNAc:betaGal beta-l ,3-N-

IPI00479361 acetylglucosaminyltransferase 4 B3GNT4

IPI00448465 Isoform 1 of Ankyrin repeat domain-containing protein 12 AN RD12

IPI00215925 Glycine N-methyltransferase GNMT

IPI00006675 Multidrug resistance-associated protein 4 ABCC4

IPI00745122 Conserved hypothetical protein MGC33894

IPI00442551 CDNA FLJ26989 fis, clone SLV03395 ATP9B

Tumor necrosis factor receptor superfamily member 16

IPI00027436 precursor NGFR

Isoform 1 of Probable DNA dC->dU-editing enzyme

IPI00005531 APOBEC-3B APOBEC3B transmembrane emp24 protein transport domain containing

IPI00023542 9 TMED9

IPI00783313 Glycogen phosphorylase, liver form PYGL

IPI00166190 Isoform 1 of Uncharacterized protein CI 9orfl 9 C19orfl9

IPI00383832 Protein kinase C-binding protein RAC 8 DVL3

IPI00024976 Mitochondrial import receptor subunit TOM22 homolog TOMM22

Isoform 2 of Spermatogenesis-associated protein 20

IPI00154567 precursor SPATA20

IPI00027685 C-C chemokine receptor type 1 CCR1

IPI00009335 Brain protein 16 C8orf30A

1PI00008495 NADH-ubiquinone oxidoreductase chain 4 MT-ND4

IPI00179172 Isoform 2 of Liprin-beta-1 PPFIBP1

IPI00012315 Nucleoside diphosphate kinase 3 NME3

IPI00432755 PPRR6495 FAM124A

IPI00550949 Bone morphogenetic protein 7 precursor BMP7

1PI00796777 17 kDa protein CRYAA

Several ankyrin repeat protein transcript variant 2

IPI00872928 (Fragment) ANKRD42

1PI00412647 CDNA: FLJ21792 fis, clone HEP00441 THADA

Isoform 1 of Thrombospondin type-1 domain-containing

IPI00032929 protein 1 precursor THSD1

IPI00008894 Carboxypeptidase A4 precursor CPA4

IPIOO 154451 MMS 19 nucleotide excision repair homolog MMS19

IPI00186145 Isoform 1 of Protein phosphatase 1L PPM1L

IPI00847759 DENN domain-containing protein 4B DENND4B

IP100008315 Isoform 1 of Ephrin type-B receptor 1 precursor EPHB1

IPI00386364 Olfactory receptor 2L2 OR2L2

IPI00031005 Protein kinase-like protein SgK196 FLJ23356

IPI00787414 Uncharacterized protein ENSP00000381388 MGC34829

IPI00003527 Ezrin-radixin-moesin-binding phosphoprotein 50 SLC9A3R1

IPI00218823 Isoform 1 of WW domain-binding protein 7 MLL4

IPI00019988 N-sulphoglucosamine sulphohydrolase precursor SGSH

IPI00059164 Galactose-3-O-sulfotransferase 3 GAL3ST3

IPI00873740 Uncharacterized protein ENSP00000383832 (Fragment) -

IP100060379 Integrator complex subunit 12 INTS12

IPI00032416 Isoform Long of Protein jagged-2 precursor JAG2

IPI00444706 CDNA FLJ45007 fis, clone BRA WH3012005 ALRN

IPI00216710 Isoform 1 of Nuclear receptor ROR-gamma RORC Table 6c 15

IPI00335589 RNA methyltransferase-like protein 1 RNMTL1

IPI0041 1690 Isoform 3 of La-related protein 1 LARP1

IPI00295519 Isoform 1 of Uncharacterized protein C3orfl7 C3orfl 7

transmembrane and tetratricopeptide repeat containing 4

1PI00514153 isoform 1 TMTC4

IPI00398728 Isoform 1 of Retinitis pigmentosa 1 -like 1 protein RP1 L1

IPI00843819 Similar to Dual specificity protein kinase CL 2 -

IPI00065276 Isoform 2 of Tether containing UBX domain for GLUT4 ASPSCR1

IPI00021473 59 kDa protein CBFA2T3

IPI00745775 Similar to PR domain containing 4 -

IPI00016703 24-dehydrocholesterol reductase precursor DHCR24

IP100013880 Semaphorin-5A precursor SEMA5A

IPI00010157 S-adenosylmethionine synthetase isoform type-2 MAT2A

IPI00794307 hypothetical protein LOC729505

IPI00015782 UPF0171 protein C 16orf35 C16orf35

IPI0001 1652 Isoform Efs 1 of Embryonal Fyn-associated substrate EFS

IPI00644522 PNKP protein PNKP

Isoform 1 of Chloride channel CLIC-like protein 1

IPI0004551 1 precursor CLCC1

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex

IPI00028881 subunit 3 NDUFA3

IPI00604763 Transmembrane protein 66 precursor TMEM66

IP100235647 similar to fibrillarin LOC345630

IPI00879950 15 kDa protein -

Inter-alpha-trypsin inhibitor heavy chain H5-like protein

IPI00413385 precursor ITIH5L

IPI00294910 Protein PARM-1 precursor DKFZP564O0823

IPI00022334 Ornithine aminotransferase, mitochondrial precursor OAT

IPI00023617 Zinc finger protein 197 ZNF197

IPI00008433 40S ribosomal protein S5 RPS5

IPI00642798 Nucleolar autoantigen No55 SC65

Isoform 2 of Mediator of DNA damage checkpoint protein

IPI00470805 1 MDC1

IPIOO 167089 Isoform 2 of Activated CDC42 kinase 1 TNK2

IPI00102575 ATPase family, AAA domain containing 5 ATAD5

IPI00783753 UPF0235 protein C 15orf40 C15orf40

IPI00383895 CDNA FLJ40559 fis, clone THYMU2002910 PRDM1 1

IPI00152157 Isoform 1 of Zinc finger protein 509 ZNF509

IPI00296803 30 kDa protein TCP1 1L2

IPI00020501 Myosin- 1 1 MYH1 1

IPIOO 168056 Zinc finger and BTB domain-containing protein 38 ZBTB38

Mitogen-activated protein kinase kinase 1 -interacting

IPI000309I 9 protein 1 MAP2K1 IP1

IPI00827745 Isoform 1 of RNA-binding protein 24 RBM24

Nucleotide-binding oligomerization domain-containing

IPI00005776 protein 1 NODI

IPI00026105 Isoform SCPx of Non-specific lipid-transfer protein SCP2

IPI00385255 Ig lambda chain V-II region NIG-84 -

IPI00328178 Isoform 3 of TOM 1 -like protein 2 TOM1L2

IPI00394879 Leucine-rich repeat-containing protein 9 LRRC9

IPI00401852 Conserved hypothetical protein DKFZP434L187 Table 6c 16

Table 6c 17

Table 6c 18

Table 6c 19

Table 6c 20

Table 6c 21

Table 6c 22

Table 6c 23

Table 6c 24

Table 6c 25

Table 6c 26

Table 6c 27

Table 6c 28

Table 6c 29

IPI00384051 Uncharacterized protein PSME2 PSME2

IPI00337415 Guanine nucleotide-binding protein G(i), alpha- 1 subunit GNAI 1

IPI00003377 Isoform 1 of Splicing.factor, arginine/serine-rich 7 SFRS7

IPI00006146 serum amyloid A2 SAA1 ;SAA2

IPI00017551 Isoform 1 of Regucalcin RGN ·

IPI00032338 kelch-like 20 KLHL20

Isoform 1 of Potassium voltage-gated channel subfamily

IPI00293679 QT member 4 KCNQ4

IPI00745396 Stromal RNA regulating factor HNRPLL

Isoform 3 of Sterile alpha motif domain-containing protein

IPI00604752 13 SAMD13

IPI00382534 Ig heavy chain V-II region OU -

IPI00748682 Pheromone shutdown-related, TraB family protein -

Isoform 1 of Cytidine and dCMP deaminase domain-

IPI00008444 containing protein 1 CDADC 1

IPI00792933 zinc finger protein 462 ZNF462

Succinate-semialdehyde dehydrogenase, mitochondrial

IPI00019888 precursor ALDH5A1

IPI00032597 RNA-binding motif protein, X-linked 2 RBMX2

IPI00402005 Similar to DNA-binding protein ZNF528

IPI00020036 Neuronal acetylcholine receptor subunit alpha-4 precursor CHRNA4

IPI00783855 neighbor of BRCA1 gene 1 NBR1

Osteopetrosis-associated transmembrane protein 1

IPI00329054 precursor OSTM1

IPI00028864 Neurexophilin-3 precursor NXPH3

Isoform 1 of X-linked retinitis pigmentosa GTPase

IPI00023757 regulator RPGR

IPI00746987 Ribosomal protein S 1 family protein -

IPI00295469 Copine-6 CPNE6

Isoform Mitochondrial of Malonyl-CoA decarboxylase,

1PI00000663 mitochondrial precursor MLYCD

IPI00788258 similar to lysyl oxidase-like 1 preproprotein LOXL1

IPI00739387 hypothetical protein LOC401478 FLJ45872

IPI00456599 hypothetical protein LOC84792 MGC 12966

IPI00607831 PRAME family member 3 PRAMEF3

IPI00399254 Isoform 1 of OTU domain-containing protein 4 OTUD4

IPI00164352 zinc finger protein 292 ZNF292

IPI00719505 RABL2A protein RABL2A

Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase

1PI00008913 5 ST6GALNAC5

IPI00020454 Deoxycytidine kinase DC

IPI00784880 Cancer/testis antigen 75 LOC440934

IPI00514028 21 kDa protein RNF207

IPI00884353 Ets-1 transcript variant ets-1 delta -

IPI00852725 Isoform 7 of Prolactin receptor precursor PRLR

Low-density lipoprotein receptor-related protein 2

IPI00024292 precursor LRP2

Isoform 1 of Bifunctional heparan sulfate N-deacetylase N-

IPI00005600 sulfotransferase 2 NDST2

IPI00028357 Exportin-4 XP04 Table 6c 30

Table 6c 31

Table 6c 32

IPI00240793 Probable phospholipid-transporting ATPase IF ATP1 1 B

IPI00168995 Olfactory receptor 4D9 OR4D9

IPI00024704 Uronyl 2-sulfotransferase UST

IPI00031 195 Isoform 1 of Vang-like protein 1 VANGL1

IPI00059190 Isoform 1 of SLAM family member 9 precursor SLAMF9

IPI00043467 Tigger transposable element-derived protein 1 TIGD1

IPI00376237 Isoform 2 of Transcription factor LBX2 LBX2

IPI00235842 Zinc finger protein 483 ZNF483

Isoform 2 of Calcium-transporting ATPase type 2C

IPI00220473 member 1 ATP2C 1

IP1001691 15 Olfactory receptor OR9-8 OR13C3

Isoform 1 of Phosphatidylinositol N-

IPI00020966 acetylglucosaminyltransferase subunit A PIGA

1PI00456827 Protein FAM22G precursor FAM22G

IPI00382831 Cerebral protein- 13 BAP1

IPI00477692 Uncharacterized protein ENSP00000330808 LOC131 149

Similar to Rod cGMP-specific 3',5'-cyclic

IPI00747657 phosphodiesterase subunit beta precursor PDE6B

IPI00301583 Isoform 1 of Zinc finger protein 691 ZNF691

IPI00790447 12 kDa protein -

IPI00829904 Uncharacterized protein ENSP00000374814 -

Isoform B of Phosphate carrier protein, mitochondrial

IPI00215777 precursor SLC25A3

IPI00028912 zinc finger protein 161 VEZF1

IPI00387161 Ig lambda chain V-I region VOR -

IPI00830107 V4-2 protein IGLV5-45

IPI00440493 ATP synthase subunit alpha, mitochondrial precursor ATP5A1

IPI00020533 Protein BEX1 BEX1

IPI00019242 Matrix metalloproteinase-15 precursor MMP15

Isoform 4 of Vacuolar protein sorting-associated protein

IPI00376436 13B VPS13B

IPI00029162 Isoform 2 of Cell division cycle 2-like protein kinase 5 CDC2L5

IPI00419237 Isoform 1 of Cytosol aminopeptidase LAP3

IPI00065500 BROl domain-containing protein BROX C lorf58

IPI00740336 formin 1 FMN1

IPI00017203 Protein R I 1 homolog RMI l

IPI00024664 Isoform Long of Ubiquitin carboxyl-terminal hydrolase 5 USP5

IPI00786946 similar to Tektin-3 LOC642249

IPIOO 166257 CDNA FLJ37614 fis, clone BRCOC201 1769 -

Isoform 1 of Interferon-alpha/beta receptor alpha chain

1PI00012877 precursor IFNAR1

1PI00021 199 Stathmin-3 STMN3

IPI00293431 WUGSC:H_DJ0855D21.2 protein MGC70863

Isoform A of l-phosphatidylinositol-4,5-bisphosphate

IPI00219563 phosphodiesterase beta- 1 PLCB 1

IPI00442745 CDNA FLJ26780 fis, clone PRS03837 -

1P100295400 Tryptophanyl-tRNA synthetase, cytoplasmic WARS

IPI00444330 CDNA FLJ45693 fis, clone FEBRA2012625 -

Isoform 3 of Calcium/calmodulin-dependent protein kinase

IPIOO 170509 kinase 2 CAMKK2

IPIOOO 17256 Ras suppressor protein 1 RSU 1 Table 6c 33

Table 6c 34

Table 6c 35

Table 6c 36

Table 7 L 1

Table 7 L 2

Table 7 L 3

Table 7 L 4

Table 7 L 5

Table 7 L 6

Table 7 L 7

Table 7 L 8

Table 7 L 9

Table 7 L 10

Table 7 L 11

Table 7 L 12

Table 7 L 13

Table 7 L 14

Table 7 L 15

Table 8 I 1

Table 8 I 2

Table 8 I 3

Table 8 1 4

Table 8 I 5

Table 8 I 6

Table 8 1 7

Table 8 1 8

Table 8 I 9

Table 81 10

Table 8 I 11

Table 8 I 12

Table 8 I 13

Table 81 14

Table 8 1 15

Table 81 16

Table 8 1 17

Table 8 1 18

Table 8 I 19

Table 8 I 20

Table 8 I 21

Table 8 I 22

Table 8 I 23

Table 8 1 24

Table 8 I 25

Table 8 I 26

Table 8 I 27

Table 8 I 28

Table 8 I 29

Table 8 1 30

Table 8 I 31

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 1 /14

Table 9. Quantitative Relative Abundance of CSF Proteins in Chronic Fatigue (CF) compared to Neurologic Lyme Disease. A ratio greater than 1 indicates there is a relative quantitative difference in Chronic Fatigue compared to Neurologic Lyme disease (LD). Ratios near 1 suggest equal relative abundances/ Ratios less than 1 indicate the proteins is present in a greater relative abundance in Neurologic Lyme disease compared to Chronic Fatigue. There are 168 proteins in Chronic Fatigue that are 2 fold greater in relative abundance than those proteins Neurologic Lyme disease. There are 1081 proteins that are relatively more abundant in Neurologic Lyme disease compared to Chronic Fatigue with a ratio of 0.5 or less. Blank cell is close to 0 ratio.

Table 9. Relative Abundance of CSF Proteins Fatigue compared to Neurologic Lyme 2/14

Table 9. Relative Abundance of CSF Proteins Fatigue compared to Neurologic Lyme

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 5/14

Table 9. Relative Abundance of CSF Proteins Chroni Fatigue compared to Neurologic Lyme 6/14

Table 9. Relative Abundance of CSF Proteins Fatigue compared to Neurologic Lyme

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 8/14

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 9/14

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 10 /14

IPI00020407 IPI00845229

IPI00295767 IPI00867509

IPI00004047 IPIOOO 10207

IPI00008274 IPIOOO 14398

IPI00001863 IPI00218465

IPI00743898 IPI0001 1592

IPI00290078 IPI00005158

IP100215979 IPI00410013

IPI0002531 1 IPI00218292

IPI00006470 IPI00853400

IPI00023359 IPI00748955

IPI00018708 IPI00013319

IPIOOO 1 1781 IPI00301465

IPI00033030 IPI00024853

IPI00307612 1PI00221255

IPI00002459 IPI00419836

IPI00221034 IPI00000104

IPI00021274 IPI00454910

IPI00024580 IPI00021364

IPI00185661 IPI00306884

IPI00479083 IPI00007709

IPI00045839 IPI00879575

IPI00216592 IPI00004315

IPIOO 168885 IPI00384016

IPI00642259 IPI00005159

IPI00306844 IP100024067

IPI00165229 IPI00465261

IPI00217652 IPIOO 152769

IPI00741005 IPI00432707

IPI00446588 IPI00020692

IPI00029591 IPI00647217

IPI00514893 IPI00219910

1PI00023191 IPIOOO 13281

1PI00025363 IPI00297779

IPI00009365 IPI00033600

IPI00792759 IPI00061354

IPI00219525 IPIOOO 12510

IPI00005690 IPI00216774

IPIOOO 17529 IPI00026546

1PI00218730 IPI00003441

IPI00216049 IPI00335946

IPI00383594 IPIOOO 13978

IPI00307591 IPIOO 168920

IPIOO 170766 IPI00219930 ίΡ1003021 33 IPIOO 168520

IPI00304789 IPI00028082

IPI00027744 IPI00871227

IPI00375881 IPI00396378

IPI00297550 IPI00031718

IPI00026230 IPIOO 152524

IPI00021048 IPI00646689

1PI00290857 IPI00552943 Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 1 1 /14

Table 9. Relative Abundance of CSF Proteins Fatigue compared to Neurologic Lyi

Table 9. Relative Abundance of CSF Proteins lie Fatigue compared to Neurologic Lyme 13/14

Table 9. Relative Abundance of CSF Proteins Chronic Fatigue compared to Neurologic Lyme 14 /14

TABLE 10 CSF Proteins in True Normals by IPI 1

IPI00022434 IPI00007257 IPI00853525 IPI00816741 IPI00009920 IPI00784950

IPI00783987 IPI00032291 IPI00218874 IPI00296534 IPI00300241 IPI00550731

IPI00418163 IPI00156171 IPI00215894 IP100218725 IPI00386879 IPI00472249

IPI00032258 IPI00414249 IPI00031030 IPI00027703 IPI00382606 IPI00654888

IPI00878517 IPI00878576 IPI00025276 IPI00423463 IPI00788835 IPI00792626

I I00006601 IPI00413959 IP100032328 IPI00784842 IPI00015102 IPI0017141 1

IPI00384697 IPI00021842 IPI00376427 IPI00219029 IPIOOO 13976 IPI00020996

IPI00022463 IPI00064667 IPI00456623 IPI00295542 IPI00216171 IPI00783399

IPI00069058 IPI00303210 IPI00019943 IPI00744835 IPI00439446 IPIOO 160552

IPI00798430 IPI00006608 IP100748312 IPI00012503 IPI00027780 IPI00294004

1P100478003 IPI00216728 IPI00291866 IPI00418262 IPI00162735 IPI00301865

I I00017601 I I00007921 IPI00021885 IPIOO 159927 IPI00002147 IPI00216697

IPI00292071 IPI00550991 IPI00022395 IPI00784810 IPI00294395 IPI00440577

IPI00026314 IPI00009362 IPI00289831 IPI00785084 IPI00008318 IPI00061977

1PI00029751 IPI00655702 IPI00027310 IPI0001 1229 IPI00853454 IPI00855725

IPI00289501 IPI00795918 IPI00815926 IPI00465439 IPI00027087 IPI00020986

IPI00013179 IPI00019591 IPI00302641 IPI00016334 IPI00029863 IPI00297646

IPI00514285 IPI00290315 IPI00017696 1PI00003362 IPI00029343 IPI00845354

IPI00296777 IPI00470535 IPI00375547 IPI00853369 IPI00430842 IPIOO 169383

IPI00022229 IP100291 136 IP100015260 IPI00872363 IPI00744561 IPI00004669

IP1000061 14 IPI00021841 IPI00607580 IPI00423466 IPI00784998 IPI00022426

IPI00783390 IPI00177543 IPI00784828 IPI00790899 IPIOO 166048 IPI00022284

IP100029739 IPI00394655 IPI00784807 IPI00334282 IPI00442294 IPI00328609

IPI00242956 IPI00479514 IPI00002714 1PI00019568 IPI00296922 IPI00219365

IPI00299059 IPI00639937 IPI00219798 1PI00296165 IPIOOO 16915 IPI00006662

I I00291262 IPI00021000 IPI00426051 IPI00829767 IPI00844156 IPI00004656

IPI00794184 IPI00478809 IPI00296537 IPI00292950 IPI00003351 IPI00021891

IPI00788189 IPI00022937 IPI00384542 IPI00292530 IPI00646281 IPI00018136

IP100553177 1P100032179 IPI00025465 IPI00023673 IPI00023845 IPI00001662

IPI00304273 IPI00023814 IPI00796279 IPI00303963 IPI00374563 IPI00477747

IPI00024284 IP 100220741 IPI00107831 IPI00000828 IPI00002280 IPIOO 183445

IPI00883753 IPI00019580 IPI00761 159 IPI00828205 IPI00298971 IPI00784985

IPI00847179 IPI00294193 IPI00026944 IPI00451625 IPI00029260 IPI00334667

IPI00555812 IPI00024966 IPI00472345 IPI00029658 IPI00442297 IPI00784969

IPI00333776 IPI00218192 IPI00791343 IPI00016150 IPI00830132 IPI00785067

IP100742696 IPI00218875 IPI00784894 IPI00004433 IPI00872555 IPI00430808

IPI00415032 IP100219042 1PI00018219 IPIOOO 12545 IPI00218733 IPI00477597

IPI00072917 IPI00306339 IPI00298497 IPI00025252 IPI00515041 IPI00301579

IPI00022488 IPI00296608 IPI00003802 IPI002201 17 IPIOOO 19157 IPI00290085

IPI00647027 IPI00739237 IPI00025257 IPI00784942 IPI00465028 IPI00022371

IPI00020557 IPI00009997 IPI00448925 IPI00022895 IPI00220562 IPIOO 176221

IPI00241562 IPI00305461 IPI00328829 IP100394992 IPIOO 166622 IPI00480183

IPI00607600 IPI00032293 IPI00031 121 IPI00550558 IPI00787050 IPI00855824

IPI00020012 IPI00220644 IPI00022432 IPI00298828 IPI00216704 IPI00289083

IPI00032220 IPI00334238 IPIO0641737 IPIOO 163207 IPI00647704 IPIOOO 16422 TABLE 10 CSF Proteins in True Normals by IPl 2

IPI00000779 1PI00022420 1PI00794070 IPI00015881 IPI00646304 IPI00292550

IPI00784830 IPI00298793 IPI00009802 IPI00787781 IPI00029693 IPI00027497

IPI00784758 IPI00001952 IPI00465184 IPI00026104 IPI00877169 IPI00815938

IPI00021854 IPI00152540 IPI00795013 IPI00000816 IPIOOO 10949 IPI00816555

1PI00298281 1PI00027848 IPI00385980 IPI00793166 IPI00220342 IPIOOO 15964

1PI00008787 IPI00643034 IPI00218046 IPI00299738 IPI00718977 IPI00299299

IPI0002891 1 IP 100026946 IPI00022337 IPI00022822 IPI00302181 IPI00301459

IPI00166729 IPIOO 166766 IPIOO 103175 IPI00218413 IPI00465325 IPI00290856

IPI00022417 IPIOO 154734 IPI00009865 IPI00019581 IPI00337548 IPI00029723

IPI00022431 IPI00410210 IPI00552905 IPI00006967 IPI00032532 IPI00297487

IPI00010154 IPI00008944 IPI00787853 IPIOOO 19576 IPI00643920 . IPI00027482

IPI00009028 IPI00384952 IPI00000130 1PI00028413 IPI00743766 IPI00215983

IPI00746963 IPIOO 180240 IP100829877 IPIOO 167093 IPI00000877 IPI00790473

IPI00003590 IPI00176458 IPIOOO 13698 IPIOOO 18236 IPI00423461 IPI00000137

1PI00027827 1PI0001 1218 IPIOOO 1 1264 IPI00877029 IPI00219526 IPI00477992

IP100219217 IPI00292946 IPI00163563 IPI00027166 IPI00783665 IPI00015756

IPI00465248 IPI00329775 IPI00328391 IPI0041 1680 IPI00012102 IPI00002816

IPI007921 15 IPI00024046 IPI00026216 IPI00852979 IPI00003921 IPI00023014

IP100410600 IPI00221224 IPI00783492 IPI00414984 IPIOOO 1 1261 IPI00021485

IPI00298237 IPI00297124 IPI00816626 IPI00791228 IPI00879084 IPI00293088

IPI00419722 IPI00297284 IPI00027230 IPIOO 162547 IPI00029235 IPI00020990

IPI00879665 IPIOO 102543 IPI00290283 IPI00022608 IPI00395488 IPI00745660

1PI00028908 IPI00550162 IPI00376689 IPI00024570 IPI00298994 IPI00414896

IPI00252731 IPIOO 165949 IPI00419724 IPI00008994 IPIOOO 10471 IPI00023019

IPI00012585 IPI00056478 IPI00218732 IPIOO 157414 IPI00298547 IPI00002732

IPI00021304 IPI00385264 IPI00021263 IPI00443799 IPI00220642 IPI00007221

IP100299024 IPI00418471 IPI00031461 IPI00746623 IPI00843910 IPIOOO 18769

IPI00784773 IPI00178302 IPI00293836 IPI0082971 1 IPI00002211 IPI00788786

IPI00784865 IPI00465016 IPI00220334 IPI00785196 IPI00418531 IPI00064607

IPI00008603 IPIOO 104074 IPIOO 176427 IPI00743302 IPI00025426 IPI00216691

IP100020599 IPIOOO 12887 IPI00410714 IPI00032063 IPI00022331 IPI00005142

IPI00472961 IPI00219446 IP100220327 IPI00301395 IPIOOO 10796 IPI0000161 1

IP10001 1651 IPIOO 154742 IPI00022361 IPI00328746 IPI00009793 IPI00000874

IP100027851 IPI00009950 IPIOOO 12989 IPI00298388 IPI00297263 IPIOO 163446

IPI00396423 IPIOOO 12303 IPIOO 152418 IPI00026154 IPI00871 139 IPI00027038

IPI00295741 IPI00829626 IPI00001593 IPI00217966 IPI00784156 IPIOOO 13682

IPI00853045 IPI00005794 IPIOO 166392 IPIOOO 14048 IPI00103597 IPI00745363

IPI00289819 IPI00295832 IPI00304925 IPI00023728 IPI00176193 IPIOO 106646

IPI0001 1252 IPI00004440 IPI00784519 IPI00015315 IPI00456736 IPI00005292

IPI00015688 IPI00030255 IPI00382938 IPI00247243 IPIOOO 10381 IPI00292150

IPI00020091 IPI00027350 IPI00785200 IPI00216318 IPI00003919 IPI00514676

IPI00854806 IPI00291005 IPIOOO 12440 IPI00293748 IPI00007236 IPI00376394

IPI00022429 IPI00292791 IPI00289204 IPI00829640 IPI00296176 IPI00008087

IPI00014572 IPI00027192 IPI00418446 IPI00027493 IPI00163187 IPI00014592

IPI00013303 IPI00296141 IPI00654755 IPI00026199 IPI00304962 IPIOO 183487 TABLE 10 CSF Proteins in True Normals by IPI 3

IPI00024621 IPI00152847 IPI00000138 IPIOOO 12283 IPI00306322 IP100021856

IPI00015902 IPI00003269 IPI00004946 IPI00301961 IPI00030887 IPI00056357

IPI00303071 IPI00009904 IPI00171473 IPI00025846 IPI00719621 IPI00329801

IPI00470607 IPI00007752 IPI00216882 IP10001 1732 IPI00387168 IPI00020987

IP10001 1454 IPI00477804 IPI00019399 IPI00329482 IPI00004413 IPIOOO 18274

IPI000251 10 IPI00328488 IPI00304865 IPIOOO 15049 IPI00027078 IPI00294615

IPI00291 175 1PI00022810 IPI00005908 IPI00004503 1PI00006971 IPI00029236

IPI00220292 1PI00019906 IPI00024825 IPIOOO 18206 IPI00328257 IPI00003176

IPI00009123 IPI00013475 IPIOO 168479 IPI0001591 1 IPIOOO 19502 IPI00295386

IP100299571 1PI00007702 IP100398715 IPI0001 1 140 IPI00025204 IPI00219131

IPI00002406 1PI00329352 IPI00028448 IPI00789954 IPI00027462 IPI00291006

IPI00785079 IPI00023598 IPI00002236 IPI0001 1605 IPI0047761 1 IPI00289058

IPI00852577 IPI00292304 IPI00014964 IPI00028553 IPI00216319 IPI0003231 1

IPI00871326 IPI00016870 IPIOO 103471 IPI00029061 IPIOOO 13897 IPI00023824

IPI00001477 1PI00854743 IPI00029046 IPI00301 143 IPI00304840 IPI00007797

IPI00795055 IPI00220739 IPI00791 134 IPI00060310 IPI00007750 IPI00375364

IPI0001 1654 IPI00043756 IPI0042851 1 IPI00295414 IPIOOO 18534 IPI00289870

IPI00005707 IPI00293303 IPI00412988 IPI00006154 IPIOOO 16645 IPI00005126

IPI00883772 IPI00292732 IPIOO 168884 IPIOO 168866 IPIOO 102435 IPI00031564

IPI00302592 IPI00827650 IP100465436 IPIOOO 17704 IPI00182438 IPI00034319

IPI00003865 IPI00021552 IPI00246058 IP100739827 IPI00791479 IPI00021857

IPI00003366 IPI00028614 IPI00026270 IPI00301255 IPI00299652 IPI00003102

IPI00021033 IPI00004962 IPI00290328 IPI00002525 IPI00854709 IPI00550363

IPI00010295 IPI00440580 IPI00030075 IPI00382500 IPIOO 165975 IPI00259102

IPIOO 165438 IPI00375205 IPI00296099 IPI004791 16 IPI00789847 IPIOOO 17257

IPI00219465 IPI00432592 IPI00003648 IPI00009030 IPI00642861 IPIOOO 19533

IPI00002745 IPI00031769 IPI00029605 1PI00022892 IPIOO 155729 IPI00879309

IPI00044369 IPI00045841 IPI00216983 IP100216602 IPI00409640 IPI00419595

IPI00007778 IPI00025864 IPI00025818 IPI00784258 IPI00291807 IPI00216138

IPI00022296 IPI00006644 IPIOO 178767 IPI00386630 IPI00829590 IPI00024048

IPI0047301 1 IPI00218493 IPI00029273 IP100745251 IPI00295399 IPI00642632

IPI00297224 IPI00022391 IPI00026103 IPI00008207 IPI00453473 IPI00289924

IPI00645206 IPI00333140 IPI00016679 IPI00024601 IPI00303894 IPI00328243

IPI00219757 IPI00027466 IPIOO 168626 IPI00024034 IPI00555693 IPI00031821

IPI00294705 IPI00019038 IPI00746388 IPIOOO 1 1994 IPI00006166 IPI00023751

IPI00032292 IPI00216298 IPI00830047 IPI00002925 IPI00220827 IPI00043215

IPI00217493 IPI00029193 IPI00478483 IPIOO 176424 IPIOOO 12075 IPI00412987

IPI00015346 IPI00165972 IPI00171410 IPI00337351 IPI00292300 IPI00302840

IPI00455667 IPI00745313 IPI00013569 IPI00003907 IPI00419966 IPI00022333

IPI00001895 IPI00001734 IPI00166892 IPI00060715 IPIOO 186903 IPI00385007

IPI00419585 IPI00023648 IPI00021903 IPI00402157 IPI00430291 IPI00023807

IPI00007798 IPI00006128 IPIOOO 17569 IPI00002142 IPIOOO 19954 IPI00008215

IPI00217146 1P100299503 IPIOO 167215 IPI00299086 IPI003281 13 IPI00007240

IPI007841 19 IP100022792 IPI00789234 IPI00029275 IPI00015351 IPI00292218

IPI00008290 IPI00328550 IPI00183321 IPI00374065 IPI00032288 IPI00007199 TABLE 10 CSF Proteins in True Normals by IPI 4

IPI00019190 IPI00787265 IPI00007102 IPI00218474 IPI00021833 IPIOOO 18396

IPI00018305 IPI00020906 IPI00643348 IPI00101608 IPI00218539 IPI00465315

I I00029606 IPI00740545 IPI00741710 IPI00216457 1PI00300838 IPI00026259

IPI00384391 IP100010348 IPIOO 168520 IPI00747849 IPI00006657 IPI00022394

IPI00026050 IPI00294834 IPI00153049 IPI00549330 IPI00033560 IPI00024035

IPI00031510 IPI00829947 IPI00432525 IPI00007425 IPI00025809 IPI00022392

IP100016862 IPIOO 165044 IP100152850 IPI00020984 IPI00026197 IPI00299150

IPI00021794 IPI00021275 IPI00217882 IP100554786 IPI00023576 IPI000041 14

IPI00021447 IPI00478892 IPI00297188 IP100019359 IPI00215767 IPIOOO 10896

IPI00008780 IPI00556287 IPI00099670 IPI00384404 IPI00024094 IPI00024273

IPI00296197 IPI00854841 IPI00219930 IPI00218834 IPI00827510 IPI00020977

IPI00009276 IPI00736885 IPI003871 15 IPIOOO 17841 IPI00829663 IPIOOO 1201 1

IPI00009145 IPI00016467 IPI00024129 1PI00784154 IPI00883855 IPI00028931

IPI00005474 IPI00827892 IPI00299699 IPI00006451 1PI00456589 IPI00328703

1PI00030205 IPI00479997 IPI00166339 IPI00025476 IPI00024036 IPI00030739

IPI00027377 IPI00790775 IPI00000824 IPI00827940 IPI00419720 IPI00031549

IP100029997 IPI00736860 IPI00075248 IPI00829752 IPI003871 18 IPI00293849

IPI00329685 1PI00017968 IPI00880120 IPI00749328 IPI00291395 IPI00385252

IP100218570 IPI00867665 IPI0044291 1 IPI00871227 IPI00022367 IPI00789477

IPI00306710 IP100181 174 IPI00008494 IPIOO 180707 IPI00002307 IPI00219575

IPI00431738 IPI00414467 IPI00023858 IPI00005652 IPI00001399 IPI00387120

IPI00307592 IPI00010790 IPI00027223 IPI000091 1 1 IPI00006713 IPIOOO 1 1662

IPI00410122 IPI00021983 IPI00410585 IPI00219301 IPI00827482 IPI00026991

IP1005501 15 IPI00044743 IP100299724 IPI00007709 IPI00008107 IPI000301 1 1

IPI00020672 IPI00005981 IPIOO 167710 IPIOOO 19209 IPI00783024 IPI00013162

I I00027174 IPI00006482 IPI00218414 IPI00001506 IPI00162329 IPIOOO 17745

IPI00829701 IPI00026174 IPI00465255 IPI00854667 IPI00217345 IPI00220361

IP100006803 IPI00744692 IPIOO 182944 IPI00827560 IPI00023643 IPI00374914

IPIOO 107886 IPI00794450 IPIOO 103871 IPI00007249 IPI00470484 IPI00024105

IPI00171928 IPI00401283 IPI00293128 IPI00031534 IPI00428967 IPI00470625

IPI00304331 IPI00014439 IPI00217236 IPI00217466 IPI00455739 IPI00307276

IPI00607655 IPI00025840 IPI00383732 IPI006431 15 IPI00171412 IPI00383032

IPI00816799 IPI00296058 IPI00414717 IPI00217759 IPI00182138 IPI00219425

IPI00328745 1PI0001 1302 IPI00219684 IPI00218345 IPIOOO 16666 IPIOOO 12269

IPI0001 1730 IPI00021855 IPI00027341 IPI00478890 IPI00029131 IPI00788824

IPI00783689 IPIOO 178926 IPI00008223 IPI0001 1518 IPI00293723 IPI00022959

IPI00026237 IPI00015525 IPI00414909 IPI00783184 IPI00002334 IPI00477714

IPI00386133 IPI00296992 IPI00021817 IPI00251507 IPI00478414 IPIOOO 19449

IPI00296558 IPI00302944 IPI00437751 IPIOOO 19501 IPI00019176 IPI00010182

1P100413912 IPI00784430 IPI00017567 IPI00432723 IPI00382481 IPI00292496

1P100063048 IPI00305380 IPI00219025 IPI00644472 IPI00022977 IPI00297655

1PI00003021 IPI00029699 IPIOOO 10706 IPI00217465 IPI00643667 IPI00028015

IPI00027721 IPI00001893 IPI00257508 IPIOOO 12058 IPI00219219 IPI00385253

1PI00783287 IPIOOO 12386 IP100293925 IPI00217467 IPI00293757 IPIOO 179851

IPI00013096 IPI00413451 IPI00031789 IPI00847670 IPIOOO 1 1094 IPI00021347 TABLE 10 CSF Proteins in True Normals by IPI 5

IPI00029928 IPI00008556 IPI00013701 IPIOO 165125 IPI00289862 IPI00099650

1PI00401264 1P100027463 IPI00784368 IPIOOO 12048 IPIOOO 13945 IPI00008756

IPI00015842 IPI00297252 IPI00884389 IPI00418960 IPI00465261 IPI00008164

IP100005222 IPI00303476 IPI00854644 IPIOO 168847 IPI00215997 IPI0000251 1

IP100440932 IPI00410487 IPIOOO 16621 IPIOO 168921 IPI00382476 IPI00009901

IPIOO 184019 IPI00025447 IPI003871 16 IPI00184851 IPI00024307 IPI00009477

IPI00414676 IPI00029168 IPI00384392 IPI00027507 IPI00294713 IPIOOO 12792

IPI00030871 IPI00299145 IPI00827876 IPI00081836 IPI00554752 IPI00412492

IPI00022674 IPI00005123 IPIOOO 18941 IPI00397645 IPI00306844 IPIOO 178352

IPI00000044 IPI00297181 IPI00883765 IPI00220748 IPI00384016 IPI00413587

1PI00003799 IPI003871 19 IPI00748265 IPIOOO 19771 IPI00477868 IPIOOO 17334

IPI00374732 IPI00030882 IPI00006556 IPIOOO 16014 IPI00022640 IPI00044600

IPI00289876 IPI00884080 IPI00374590 IPI00301 180 IPI00644346 IPIOOO 12007

IPI00300725 IPI0041 1656 IPIOOO 18860 IPI00005038 IPI00027847 IPI00441498

IP100018381 IPI00375879 IPI00556391 IPIOOO 10402 IPI00009867 IPI00004457

IPI00028082 IP100032050 IPI0088371 1 IPI00303161 IPI00002966 IPI00382493

IPI00009826 IPI00026285 IPI00441344 IPI00022389 IPI00029756 IPI00337612

IP100220301 IPI00402293 IPIOOO 19862 IPI00419442 IPI00007853 IPI00024466

IPI00006130 IPI00384402 IPIOOO 19600 IPI00004573 IPI00465322 IPIOOO 12009

IPIOO 157454 IPI00829740 IPI00827829 IPI00257882 IPIOO 103755 IPI00217963

IPI00062037 IPI00006444 IPI00829841 IPI00293276 IPI00550533 IPI00382488

IPI00019755 IPI00024929 IPI00031506 IPI00025812 IPI00002283 IPI00022445

IP100220362 IPI00020747 IPI00293539 IPI00291488 IPI00419565 IPI00006510

IPI00739099 IPI00829812 IPIOOO 10470 IPI00382478 IPI00029623 IPI00000914

IPI00220766 IPI00293971 IPIOOO 1 1899 IPI00007047 IPI00171 199 IPI00299116

IPI00552852 IPI00884092 IPI00024587 IPI00413641 IPIOO 149097 IPI00400935

IPIOO 107731 IPI00022891 IPI00005516 IPI00027444 IPI00021834 IPI00783156

IPI00293464 IPI00783393 IPIOOO 12510 IPI00299083 IPI00001610 IPIOO 176581

IPI00018146 IPIOO 176398 IPI00217376 IPI00299547 IPI00001592 IPI00023191

IPI00029817 IPIOOO 17562 IPI00553138 IPIOO 170814 IPI00382682 IPI00217005

IPI00219129 IPI00010148 IPI00020396 IPI00009890 IPI00061354 IPI00219682

IPIOO 184094 IPI00883879 IPI00000832 IPI00219468 IPI00009054 IPI00029700

IPI00219910 IPI00299399 IPI00760721 IPI00413344 IPI00297779 IPI00024919

IPI00398918 IPI00022649 IPI00465377 IPI00008586 IPI00168920 IPI00022039

IPI00552267 IPI00001633 IPI00828105 IPI00006524 IPI00215980 IPI00004047

IPI00031708 IPI00171438 IPI00743194 IPI00026800 IPIOO 100154 IPI00387106

IPI00022774 IPI00376131 IPI00387024 IPI00216461 IPI00021997 IPI00305975

IPI00026240 IPI00005517 IPI00444605 IPI00735451 IPI00418169 IPI00440493

IPI00005722 IPI00827581 IPI00304577 IPI00075013 IPIOOO 12315 IPI00419237

IPIOO 169285 IPI00827637 IPI00301364 IPI00006009 IPI00552943 IPI00024067

IPI00396378 IPI00298650 IPI00030847 IPI00329332 IPI00008726 IPI00218795

IPI00299758 IPI00873863 IPI00008533 IPI00384400 IPI00021727 IPI00382482

IPI00007960 IPI00000760 IPI00657742 IPI00033466 IPI0041 1706 IPI00292657

IPI003871 17 IPIOO 102575 IPI00218667 IPI00289926 IPI00027972 IPI00216694

IPI00005809 IPI00472754 IPI00008997 IPIOOO 16371 IPI00383951 IPI00384395 TABLE 10 CSF Proteins in True Normals by IPI 6

IPI00023754 IPI00432766 IPI00219067 IPI00021091 IPIOOO 13933 IPI00216914

IPI00019904 IPI00300623 IPI00410079 IPI00021695 IPI00024248 IPI00399252

IPI00829827 IPI0001 1865 IPI00827929 IPI00413781 IPI00028714 IPIOO 144243

I I00219806 IPI00015479 IPI00019812 IPI00480159 IPI00063827 IPIOO 186004

IPI00873344 IPI00294619 IPI00010343 IPI00005690 IPI00215899 IPI00000070

IPI00552939 IPI00003441 IPI00023942 IPI00289746 IPI00412264 IPI00255145

IPI00827939 IPI00043810 IPI00305833 IPI00295767 IPI00024887 IPI00552874

1PI00065312 IPI00024976 1PI00550746 1PI00296441 IPI00005837 IPIOOO 10737

IP100152524 1PI00550949 IPI00003470 IPI00827906 IPI00024138 IPIOO 168806

IPI00182194 IP100006034 IPI00028387 IPI00383887 IPI00335946 IPI00302850

IPI00165936 IPI00297180 IPI00009396 IPI00385985 IPI00807609 IPIOOO 13681

IPI00783818 IPI00003527 IPI00828156 IPI00064652 IPI00021900 IPI00019208

IPI00242905 IPI00061520 IPI00181743 IPI00024572 IPI00026358 IPI00025019

IPI00022890 IPI00219420 IPI00426727 IPI00384407 IPI00030877 IPI00013508

IPI00026546 IPI00005774 IPI00552937 IPI00030431 IPI00000265 IPI00470766

IP100293460 IPI00879950 IPI00787936 IPI00220706 IPI00386575 IPI00023359

IPI00032227 IPI00004494 IPI00031907 IPI00028193 IPI00000190 IPI00031696

IPI00064377 IPI00396383 IPIOOO 18879 IPI00000775 IPI00790122 IPI00038378

1PI00816775 IPI00454695 IPI00399089 IPI00221 1 17 1PI00026125 IPI00029819

IP100298476 IPI00031718 IPI00387097 IP100646689 IPI00002818 IPI00003933

IPI00830035 IPI00021 119 IPI00007812 IPI00218319 IPI00296259 IPIOO 184997

IPI00002320 IP100004488 IPIOO 170692 IPI00004367 IPI00642645 IPI00004409

IPI00166613 IPI00514517 IPI00854707 IPI00029591 IPI00386131 IPI00556643

IPI00001 120 IPI00009439 IPI00788258 IPI00552578 IPIOOO 13290 IPI00000792

IP100382442 1PI00008504 IPI00410675 IPI00301288 IPI00154858 IPI00218130

IPI00008202 IPI00789259 IPI00045536 IPI00000160 IPI0000081 1 IPI00292393

IPI00024580 IPI00017557 IPI00019180 IPI00032405 IPI00005719 IPI00221332

IPI00328431 IPI00014223 IPI00008085 IPIOOO 12948 IPI00217264 IPI00046057

IPI00829834 IPI00216699 IPI00329538 IPI00307612 IPI00218628 IPI00021364

IPI00306576 IPI00044707 IPI00030634 IPI00025992 IPI00217405 IPI00061507

IPI00854624 IPI00216348 IPI00550677 IPI00027875 IPI00554521 IPI00382499

IPI00003391 IPIOO 176104 IPI00029050 IPIOOO 10442 IPI00456670 IPI00386754

IPIOO 178727 IPI00328826 IPI00328520 IPI003871 13 IPI00002535 IPI00737969

IPI00383680 1PI00151036 IPI00749514 IPI0003141 1 IPI00006900 IPI00442121

IPI00000871 1PI00020407 IPI00220281 IPI00738499 IPI00291922 IPIOO 186826

IPI00181079 IPI00289802 IPI00000087 IPI00797310 IPI00031 131 IPI00013219

IP100020884 IPI00328587 IPI00010810 IPI00853073 IPI00017163 IPIOOO 10207

IPI00008148 IPI00387105 IPI00301812 IPI00303318 IPI00026665 IPI00737429

IPI00018246 IPI00396961 IPI00027239 1PI00025318 IPI00003406 IPI00004480

IPI00827839 IPI00024689 IPI00847652 IPI00027547 IPI00020008 IPI00412216

IPI00640292 IPI00741608 IPI00250724 IPI00413778 IPI003871 10 IPI00005969

IPI00396930 IPI00414294 IPI00024704 IPI00022314 IPI00376087 IPI00060308

1PI00829810 I I00019907 IPI00646291 IPI00645194 IPI00008282 IPI003871O1

IPI00001872 IPI00328680 IPI00021 199 IPIOOO 13299 IPI00007277 IPI00218075

IPI00175989 IPI00026031 IPI00020692 IPI00743963 IPI00179589 IPI00002790 TABLE 10 CSF Proteins in True Normals by IPl 7

IPI00221034 1PI00216049 IPI00289861 IPI00301058 IPI00243995 1PI00879575

IPI00O 19372 IP1000031 1 1 IPI00855918 IPI00853516 IPI00171 196 IPI00744825

IPI00215979 IPI00003031 IPI00032313 IPI00384051 IPI00021327 IPI00005675

IPI00216963 IPI00009532 IPI00027626 IPI00006146 IPI00023505 IPI00217989

1P100248596 IPI00643937 IPI00001960 IPIOO 150881 IPIOOO 15988 IPI00829836

IPI00012391 IPI00030876 IPI00027009 IPI00024346 IPI00021812 IPIOO 185661

IPI00296337 IPI00031627 IPI00005132 IPI00296913 IPI00219077 IPI00217258

IP100299147 IPI00737920 IPI00215746 IPIOOO 18342 IPI00004084 IPI00307729

IPI00435925 IPI00218914 IPI00216780 IPIOO 166075 IPI00642259 IPI00604430

IPI00008274 IPI00456578 IPI00385918 IPI00029107 IPI00789398 IPIOO 186621

IPI00410588 IPI00013302 IPI00218820 IPI00867509 IPI00032826 IPI00295098

IPI00004534 IP100333197 IPI00383603 IPI00217871 IPIOO 152326 IPI00071824

IPI00554474 IP100004346 IPI00219622 IPI00552771 IPI00044751 IPI00747494

IPI00479669 IPI00218131 IPI00031086 IPI00410488 IPI00009943 IPI00302962

IPI00017940 1PI00440153 IPI00022462 IPI00382474 IPIOO 166807 IPI00879409

IPI00400986 IP100014516 IPI000161 12 IPI00215610 IPI00032187 IPI00005153

IPI0001 1643 IPI00297208 IPI00010193 IPI00015148 IPI00420014 IPIOO 169259

IPI00748955 1PI00025084 IPI00021048 IPI00020431 IPI00386314 IPIOO 106506

1PI00217781 IPIOOO 14899 IPI00149375 IPI00410657 IPI00024107 IPI00472332

1PI00031008 IPI00218398 IPIOOO 15913 IPI00552591 IPIOO 160369 IPI00789245

IP100103552 IPIOOO 13978 IPI00383016 IPI00335168 IPI00002478 IPIOOO 12044

IPI00443909 IPIOOO 14398 IPI00382486 IPI00002491 IPI00027438 IPI00290744

IPI00024853 IPI00874156 IPI00004533 IP100005159 IPI00033030 IPIOO 152145

IPI00101927 IPI00004373 IPI00020019 IPI00647217 IPIOOO 17964 IPI00021770

IPI00470838 IPI00827522 IPI00026241 IPIOOO 17529 IPI00163724 IPI00465045

IPI00008580 IPI00007010 IPIOOO 10863 IPI00024664 IPI00478640 IPIOOO 18803

IPI00025869 IPI00002412 IPI00218918 IPI00004798 IPI00383953 IPI00828083

IPI00005531 IPI00299778 IPI00295577 IPIOOO 12877 IPIOOO 1 1051 IPI00827580

IPI00783313 IPI00451429 IPI00029372 IPI00478816 IPI00830051 IPI00021594

IPI00009335 IPI00218407 IPI00220271 IPIOOO 17256 IPI00550720 IPIOOO 10360

1PI00387095 IPIOOO 10369 IPI00306853 IP100023217 IPI00103510 IPI00028381

1PI00013860 IPI00219005 IPIOOO 19530 IPI00477616 IPI00373872 IPI00465044

IPI00377045 IPIOOO 13004 IPI00456683 IP100479722 IPI00295172 IPIOOO 13847

IPI00008433 IPI00289334 IP100005614 IPI00006470 IPI00328522 IPIOO 180386

IPI00219525 IPI00021907 IPI00021831 IPI00021753 IPI00251596 IPI00001793

IPI00020501 IPI00008303 IPI00007682 IPI00027984 IPI00550906 IPIOO 167638

IPI00442865 IPI00064935 IPI00024502 IPI00221255 IPI00550263 IPI00827891

IPI00414320 IPI00300407 IPI00298738 IPI00300207 IPI00045219 IPI00218292

IPI00827584 IPI00061448 IPI00335541 IPIOO 171678 IPIOO 179473 IPI00384861

IPI00295618 IPI00550364 IPI00444331 IPIOOO 18909 IPI00221235 IPIOOO 18980

IPI00010133 IPI00028450 IPI00028600 IPI00163851 IPIOO 167560 IPI00830044

IPI00013991 IPI00218465 IPI00456635 IPIOOO 14340 IPI00098902 IPI00024012

1PI00005705 IPI00217740 IPI00221 178 IPI00297550 IPI00000959 IPI00478860

IP100303882 IPI00872550 IPI00000977 IPI00299263 IPI00289271 IPI00552735

IPI00154528 IPI00382421 IPI00290854 IPIOOO 14537 IPI00216470 IPI00000104 TABLE 10 CSF Proteins in True Normals by IPI 8

IPI00296219 IPI00306959 IPI00021274 IPI00028932 IPIOOO 1 1400 IPI00448465

IPI00005564 IPI00816737 IPI00394820 IPIOOO 18708 IPI00299485 IPI00745122

IPI00014850 IPI00013466 1PI00419253 IPI0001 1578 IPI00060146 IPI00783471

IPI00794679 IP100016605 IPI00029012 IPI00387159 IPI00329688 IPI00023542

IPI00294519 IP100872861 IP100043201 IPI00645089 IPI00022989 IPI00383832

1PI0074481 1 IPI00298285 1P100385042 IPIOO 167619 IPIOO 152072

IPI00031485 IPI00166619 IPI00410013 IPI00374862 IPI00060546 IPI00027685

IPI00784044 IPI00029722 1PI00402144 IP100009377 IPI00412541 IPI00432755

IPI00514893 IPI00005128 IPI00478986 IP100300244 IPI00043978 IPI00796777

IPI00429191 IPI00796647 IPI00478521 IPI00333410 IPI00440221 IPI00008894

IP100514594 1PI00852758 IPI00420071 IPIOOO 1831 1 IPIOOO 1 1564 IPI00847759

IP100853376 IPI00023087 IPI00555614 IPIOO 168862 IPI00423683 IPI00008315

IPI00400967 IPI00297444 IPI00026530 IPI00025647 IPI00026612 IPI00031005

IPI00166010 IPI00161 1 19 IPI00025700 IPI00027429 IPI00167137 IPI00787414

IPI00793576 IPI00016577 IPI00016949 IPIOOO 13281 IPIOO 155447 IPI00019988

IPI00301631 IPI00852633 IPI00297040 IPI00252845 IPI00001434 IPI00059164

IPI00396077 IPI00163391 IPI00454910 IPI0017161 1 IPI00854745 IPI00175654

IPI00465178 IPI00299679 IPI00031547 IPI00477361 IPI00043731 IPI00873740

IPI00291463 IPI00797699 IPI00384722 IPI00397578 IPI00645814 IPI00032416

IPI00007040 1PI00333126 IPI00382756 IPI00031019 IPI00003353 IPI00335589

1PI00220578 1P1007941 19 IPI00604599 IPIOOO 17659 IPI00007402 IPI00843819

IP100740191 IPI00816274 IPI00743284 IPI00744706 IPIOO 152470 IPI00065276

IP100044607 IPI00032830 IPI00021363 IPI00025094 IPI00006094 IPI00644522

IPI00301923 IPI00171737 IPI00749440 IPI00830057 IPIOO 169426 IPI0004551 1

IPI00059395 IPI00385003 IPI00216683 IPI00023315 IPI00816794 IPI00604763

IPI00030319 IPI00029123 IPI00015522 IPIOOO 10895 IPIOOO 10346 IPI00829759

IPI00018275 1PI00218487 IPI00877084 IPI00739106 IPIOOO 13216 IPI00235647

IPI00025363 IPI00158992 IPI00060265 IPI00022606 IPI00216572 IPI00294910

IPI00015285 IPI00394712 IPI00024802 IPI00550232 IPI00644025 IPI00217652

IPI00554799 IPI00001869 IPI00374039 IPI00295502 IPI00171647 IPI00470805

1PI00478124 IPI00027834 IPI00302133 IPI00216106 IPI00020058 IPIOO 167089

IPI00304596 IPI00062730 1PI00028786 IPI000101 18 IPI00026570 IPI00385143

IPI00012895 IPI00298258 IPIOO 167254 IPI00300990 IPI00027726 IPI00783753

IPI00299627 IPI00018352 IPIOOO 13455 IPI00741780 IPI00064241 IPI00445716

IPI00023513 IPI00744366 1PI00026299 IPI00454858 IPI00295503 IPI00030919

IPI00394870 IPI00008905 IPI00845508 IPI00399328 IPI00307591 IPI00827745

IPI00166817 IP100377077 IPI00745300 IPI00479083 IPI00290292 IPI00005776

IPI00375174 IPI00009294 IPI00009148 IPI00168885 IPI00003348 IPI00394879

IPI00296866 IPI00186581 1PI00787932 IPI00010575 IPI00299435 IPI00401852

IPI00040730 IPI00445364 IPIOO 166161 IPI00785015 IPI00029533 IPI00306884

1PI00829980 IPI00021985 IPIOO 180426 IPIOO 106502 IPI00815786 IPI00748891

IPI00028561 IPI00166071 IPI00382420 IPI00830025 IPI00375881 IPI00874023

IPI00743898 IPI00217023 IPI00166553 IPI00187143 IPI00008998 IPI00020199

IP100644231 IPI00455521 IPI00004315 IPI00103630 IPI006581 12 IPI00297714

IPI00007193 IPI00034006 IPI00796906 IPI00216508 IPI00479361 IPI00005158 TABLE 10 CSF Proteins in True Normals by IPI 9

IPI00791513 IPI00220791 IPI00166039 IPIOO 169331 IPIOOO 15980 IPIOOO 18098

1PI00013319 IPIOOO 15983 IPI00009899 IPI00783464 IPI00830122 IPI00243338

IPI00828037 IPI00289965 IPI00005129 IPI00298702 IPI00641251 IPI00786937

IPI00020201 IPI00374129 IPI00217948 IPI00185088 IPI00103853 IPI00027744

IPI00217537 IP100007617 IPI00027457 IPIOOO 10405 IPI00301465 IPI00718806

IPI00002884 IPI00297288 IPI00002993 IPI00873774 IPIOO 102678 IPI00024032

IPI00025092 IP100748890 IPI00555600 IPI00847335 IPI00020356 IPI00744226

IPI00003363 IPI00376587 IP100419221 1PI00877800 IPI00008226 IPI00792229

IPI00022078 IPI00297251 IPI00021634 IPI00008497 IPIOOO 10903 IPI00000144

IPI00290857 IPI00438170 IPI00384225 IPIOOO 10808 IPI00735934 IPI00786893

IPI00164949 IPI00373823 IPI00375803 IPI00827485 1PI00465234 IPIOOO 15954

1PI00029647 IPI00550917 IPI00023184 IPI00514622 IPIOOO 10303 IPI00099838

IP100414481 IPI00301294 IPI00872739 IPI00009203 IPI00008091 IPI00397949

IP100640818 IPI00021951 IPI00241409 IPI00790021 IPI00329791 IPI00418735

IPIOO 164861 IPI00815893 IPI00090764 IPI00000027 IPIOO 152344 IPI00306413

IPI0041 1674 IPI00002243 IPI00141938 IPI00033600 IPI00465363 IPIOOO 18755

IPI00025365 IPIOO 159049 IPI00024253 IPI00375746 IPI00028601 IPI00385543

IPI00020131 IPI00297277 IPI00387096 IPI00180384 IPIOOO 1 1781 IPI00299076

IP100828191 IPI00031765 IPI00218637 IPIOO 176920 IPI00419908 IPI00386393

IP100249982 IPIOOO 16685 IPI00216921 IPI00045839 IPI00479125 IPI0087851 1

IP100025473 IPI00002191 IPI0001 1416 IPI00008404 IPI00455852 IPI00816155

IP100328270 IPI00007928 IPI00260755 IPI00658025 IPIOO 174976 IPI00442564

IP100432707 IPI00022542 IPI00337385 IPI00022958 IPI00550876 IPI00412408

IP100442544 IPI00028053 IPI00304527 IPI00006987 IPI00795481 IPI00008422

IPIOO 175019 IPI00005732 IPI00000459 IPI00023162 IPI00064296 IPI00746177

IPI00027898 IPI00293095 IPI00030741 IPI00019146 IPI00002459 IPI00550792

IPI00019485 IPI00747142 IPI00399296 IPI00789181 IPI0002531 1 IPI00029175

IPI00023340 IPI00040900 IPI00233358 IPI00742725 IPI00216651 IPI00045360

IPI00300052 IPI0001 1515 IPI00879842 IPI00878755 IPI00216774 IPI00001755

IPI00383594 IPIOO 164066 IPI00021476 IPI00152050 IPI00792945 IPI00749171

IPI00019158 IPI00307702 IPI00028383 IPI00385480 IPI00027464 IPI00033419

1PI00005605 IPI0030761 1 IPI00001863 IPI00465123 IPI00293530 IPIOO 170635

IPI00045928 IPIOOO 14444 IPI00298337 IPIOOO 13495 IPI00399180 IPI00830018

IPI00306332 IPI00479217 IPI00044842 IPI00398992 IPI00007512 IPI00026230

IPI00015047 IPIOO 183206 IPI00022055 1PI00827724 IPIOOO 16576 IPI00009365

IP100001786 IPI00220070 IPI00328260 IPIOOO 12441 IPI00290308 IPI00445278

IPI00745103 1PI00023322 IPI00807418 IPI00006054 IPI00005859 IPI00644840

IPI00827846 IPI00784739 IPIOO 183002 IPI00008438 IPI00025622 IPI00301098

IPI00385791 IPI00738920 IPI00163601 IPIOO 152849 IPIOOO 19901 IPI00009771

IPIOO 145805 IPI00056314 IPI00428741 IPI00029556 IPIOO 102808 IPI00444842

IPI00296374 IPI00797694 IPI00006252 IPI00217012 IPI00073763 IPI00023152

IPI00021733 IPI00294210 IPI00007321 IPI00218730 IPIOOO 18208 IPI00296727

IPIOO 184884 IPI00787020 IPI00217617 IPI00215914 IPIOO 166865 IPI00005347

IPI00103874 IPIOO 167941 IPI00306850 IPI00290826 IPI00477468 IPI00470913

IPI00243221 IPIOOO 16701 IPI00024662 IPI00553092 IPI00005668 IPI00023407 TABLE 10 CSF Proteins in True Normals by IPI

IPI00306046 IPI00884353 IPI00217831 IPI00657936 IPI0043471 1

IPI00445315 IPI00852725 IPI00030037 IPI00329593 IPI00009881

IPI00065931 IPI00005600 IPI00013749 IPI00296461 IPI00020329

IPI00149044 IPI00791593 IPI00645078 IPI00376383 IPI00243451

IPI00007834 IPI00293396 IPI00395866 IPIOOO 15973 IPIOO 184650

IPI00003971 IPI00018914 IPI00240793 IPI00304789 1PI00328298

IPI00746681 IPI00185146 IPI00376237 IPI00792759 1PI00386284

IPI00383808 IPI00143753 IPI00847723 IPI00446588 IPI00289329

IPI00871556 IPI00217791 IPIOO 1691 15 IPI00419836 IPIOOO 18429

IPI00746666 IPIOO 167006 1P100020966 IPI00217435 IPI00032904

1PI00003814 IPI00028481 IPI00456827 IPI00021766 IPI004241 19

IPI00245940 IPI00294215 IPI00747657 IPI00221006 IPI00387004

IPI00657699 1PI00027806 IPI00215777 IPI00290358 IPI00218946

IPI00290094 IPI00071 185 IPI00028912 IPIOOO 13272 IPI00024766

IPI00413826 IPIOO 166776 IPI00003807 IPI00009070 IPI00009471

IPI00030706 IPI00853400 IPI00830107 IPI00386576 IPI00455967

IPI00410093 IPI00473033 IP100019242 IPI00022295 IPIOO 186966

IPI00168404 IPI00749245 IPI00786946 IP100747420 IPI00045939

IPI00644766 IPIOO 152182 IPIOO 166257 IPI00432226 IPIOOl 65009

IPI00167154 IPI00783604 IPIOOO 1 1592 IPIOO 171874 IPI00374670

IPI00871533 IPI00456969 IPI00442745 IPIOO 165229 IPI00289837

IPI00877615 IPI00001796 IPI00374301 IPI00006746

IPI00030352 IPI00549972 IPI00024920 IPIOO 178894

IP100221080 IPI00604551 IPI00026262 IPI00878436

IPI00032338 IPI00470468 IPI00018843 IPI00640810

IPI00293679 IPI00382515 IPI00027782 IPI00845229

IPIOO 152769 IPI00853312 IPI00030009 IPI00306549

IPI00748682 IPI00644191 IPI00177878 IPI00003392

IPI00019888 IPI00470490 IPIOO 104907 IPI00293361

IPI00291987 IPI00001433 IPI00827978 IPI00827788

IPIOO 170766 IPI00220156 IPI00005107 IPI00253281

IPI00032597 IPI00024818 IPIOO 152216 IPI00005607

IPI00783855 IPI00335437 IPI00028520 IPIOOO 14371

IPI00746987 IPI00000076 IPI00027264 IPI00329605

IPI00295469 IPI00290078 IPI00878962 IPI00032425

IPI00044326 IPI00100980 IPIOO 103891 IPI00300020

IPI00884004 IPI00328361 IPI00328709 IPI00001568

IPI00478997 IPI00022277 IPI00398154 IPI00020470

IPI00456599 IPI00216288 IPI00291939 IPI00718821

IPI00607831 IPI00025499 IPI00444272 IPI00018387

IPI00399254 IPI00030757 IPI00641 181 IPI00398229

IPIOO 171230 IPI00787083 IPI00418125 IPI00027248

IPI00719505 IPI00856012 IPI00151990 IPI00438286

IPI00784880 IPI00001712 IPI00024272 IPI00023780

IPI00741005 IPI00216592 IPI00003384 IPIOOO 18027

Claims

What is claimed is:

1. A method for diagnosing multiple sclerosis in a patient, the method comprising:

a) isolating a biological sample from the patient; and

b) analyzing the biological sample for expression of a panel of biomarkers, wherein the panel of biomarkers is set forth in any one of Tables lm, 3m, 4H-m or 2m, to determine if at least one of the biomarkers listed in any one of Tables lm, 3m, 4H-m or Table 2m is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis of multiple sclerosis in the patient.

2. The method of claim 1 , wherein the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table l m, 3m, or 4H-m, and the presence of the at least one biomarker indicates a positive diagnosis of multiple sclerosis.

3. The method of claim 1 , wherein the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 2m and the absence of the at least one biomarker indicates a positive diagnosis of multiple sclerosis.

4. A method for differentially diagnosing a neuropsychiatric disease in a patient, wherein the patient exhibits clinical symptoms common to both Neurologic Lyme disease and Chronic Fatigue

Syndrome, the method comprising:

a) isolating a biological sample from the patient; and

b) analyzing the biological sample for expression of a first panel of biomarkers, wherein the first panel of biomarkers is set forth in any one of Tables 4H-1, 7L, or 8L, to determine if at least one of the biomarkers listed in any one of Tables 4H-1, 7L, or 8L is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis of Neurologic Lyme disease.

5. The method of claim 4, wherein the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-1 or 7L and the presence of the at least one biomarker indicates a positive diagnosis of Neurologic Lyme disease.

6. The method of claim 4, wherein the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 8L and the absence of the at least one biomarker indicates a positive diagnosis of Neurologic Lyme disease.

7. The method of claim 4, further comprising analyzing the biological sample for expression of a second panel of biomarkers, wherein the second panel of biomarkers is set forth in any one of Tables 4H-c, 5c, or 6c, to determine if at least one of the biomarkers listed in any one of Tables 4H-c, 5c, or 6c is identified in the biological sample, wherein identification of at least one of the biomarkers in the biological sample indicates a positive diagnosis of Chronic Fatigue Syndrome.

8. The method of claim 7, wherein the at least one biomarker identified in the biological sample is present in the biological sample and set forth in Table 4H-c or 5c and the presence of the at least one biomarker indicates a positive diagnosis of Chronic Fatigue Syndrome.

9. The method of claim 7, wherein the at least one biomarker identified in the biological sample is absent from the biological sample and set forth in Table 6c and the absence of the at least one biomarker indicates a positive diagnosis of Chronic Fatigue Syndrome.

10. The method of claim 1 or 4, wherein the biological sample is cerebrospinal fluid, blood or a component thereof, tissue or tissue-related fluids, urine, or saliva.

1 1. A method for diagnosing a neuropsychiatric disease in a patient, wherein the patient exhibits clinical symptoms common to both Chronic Fatigue Syndrome and Neurologic Lyme disease, the method comprising:

a) isolating a biological sample from the patient;

b) analyzing the biological sample to evaluate expression levels of the biomarkers listed in Table 9 to determine a first level of at least one of the biomarkers indicative of the presence of the neuropsychiatric disease in the biological sample; and c) comparing the first level of the at least one of the biomarkers to a second level of the at least one of the biomarkers determined for a subject, wherein the subject does not have the neuropsychiatric disease, and wherein at least a two-fold difference in the ratio of the first level to the second level indicates a positive diagnosis of the neuropsychiatric disease.

12. The method of claim 1 1 , wherein the neuropsychiatric disease is Chronic Fatigue Syndrome or Neurologic Lyme disease.

13. The method of claim 1 1 , wherein the at least a two-fold difference is at least a two-fold increase or at least a two-fold decrease.

14. The method of claim 1 1, wherein the subject is a healthy subject.

15. A kit for diagnosing multiple sclerosis, wherein the kit comprises probes for detecting expression of at least one biomarker listed in Table lm, 3m, 4H-m, or Table 2m, wherein detectable expression of at least one biomarker listed in Table lm, 3m, or 4H-m is indicative of a positive diagnosis of multiple sclerosis and wherein an absence of detectable expression of at least one biomarker listed in Table 2m is indicative of a positive diagnosis of multiple sclerosis.

16. A kit for diagnosing Chronic Fatigue Syndrome, wherein the kit comprises probes for detecting expression of at least one biomarker listed in Table 4H-c, 5c, or Table 6c, wherein detectable expression of at least one biomarker listed in Table 4H-c or 5c is indicative of a positive diagnosis of Chronic Fatigue Syndrome and wherein an absence of detectable expression of at least one biomarker listed in Table 6c is indicative of a positive diagnosis of Chronic Fatigue Syndrome.

17. A kit for diagnosing Neurologic Lyme Disease, wherein the kit comprises probes for detecting expression of at least one biomarker listed in Table 7L or Table 8L, wherein detectable expression of at least one biomarker listed in Table 7L is indicative of a positive diagnosis of Neurologic Lyme Disease and wherein an absence of detectable expression of at least one biomarker listed in Table 8L is indicative of a positive diagnosis of Neurologic Lyme Disease.

18. The kit of claim 15, 16, or 17, wherein the kit comprises probes for detecting expression of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 of the biomarkers listed in any one of Tables lm, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L, wherein the number of biomarkers listed in any one of Tables lm, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L establishes the upper limit of biomarkers detected by the kit.

19. The kit of claim 15, 16, or 17, wherein the kit comprises probes for detecting expression of all of the biomarkers listed in any one of Tables l m, 3m, 4H-m, 2m, 4H-c, 5c, 6c, 7L or 8L.

20. The kit of any one of claims 16-19, wherein the probes are immobilized on a solid surface.

21. A diagnostic signature of biomarkers for diagnosing a neuropsychiatric disease, wherein the presence or absence of at least one biomarker indicates a positive diagnosis of the neuropsychiatric disease.

22. The diagnostic signature of biomarkers of claim 21, wherein the neuropsychiatric disease is multiple sclerosis, Chronic Fatigue Syndrome, or Neurologic Lyme Disease.

23. The diagnostic signature of claim 21, wherein the presence of at least one biomarker listed in Table lm, 3m, or 4H-m indicates a positive diagnosis of multiple sclerosis and is a diagnostic signature of multiple sclerosis.

24. The diagnostic signature of claim 21 , wherein the absence of at least one biomarker listed in Table 2m indicates a positive diagnosis of multiple sclerosis and is a diagnostic signature of multiple sclerosis.

25. The diagnostic signature of claim 21 , wherein the presence of at least one biomarker listed in Table 4H-c or 5c indicates a positive diagnosis of Chronic Fatigue Syndrome and is a diagnostic signature of Chronic Fatigue Syndrome.

26. The diagnostic signature of claim 21, wherein the absence of at least one biomarker listed in Table 6c indicates a positive diagnosis of Chronic Fatigue Syndrome and is a diagnostic signature of Chronic Fatigue Syndrome.

27. The diagnostic signature of claim 21 , wherein the presence of at least one biomarker listed in Table 7L indicates a positive diagnosis of Neurologic Lyme Disease and is a diagnostic signature of Neurologic Lyme Disease.

28. The diagnostic signature of claim 21, wherein the absence of at least one biomarker listed in Table 8L indicates a positive diagnosis of Neurologic Lyme Disease and is a diagnostic signature of Neurologic Lyme Disease.